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MicroRNAs (miRNAs) are short, non-coding RNA molecules that fine tune 
posttranscriptional protein expression. Aging is accompanied by progressive declines in 
muscle mass and strength, and in bone mineral density (BMD). Although miRNAs in 
pathology have been extensively studied, the role of circulating miRNAs (c-miRNAs) 
in osteoporosis and sarcopenia has to date not been well studied. Purposes: 1) To 
identify specific c-miRNAs that are associated with bone and muscle status in 
postmenopausal women and to evaluate the use of these c-miRNAs as biomarkers of 
osteoporosis and sarcopenia; and 2) to determine the associations between specific c-
miRNAs and muscle and bone variables. Methods: Seventy-five postmenopausal 
women aged 60 to 85 years old participated in this study. Body composition and areal 
BMD (aBMD) were measured by DXA. Volumetric BMD (vBMD) and bone strength 
were measured by pQCT. Muscle performance tests, including grip strength, gait speed, 
and countermovement jumps, were assessed. Bone status was classified based on 
aBMD T-scores: Osteopenia (-2.5 ≤ aBMD T-score ≤ -1) and osteoporosis (aBMD T-
score ≤ -2.5). Two sets of criteria were used to classify sarcopenia status: 1) skeletal 
muscle mass index (SMI) < 5.5 kg/m2; and 2) SMI < 5.5 kg/m2 and low muscle strength 
(grip strength < 20 kg) or low gait speed (<0.8 m/s). Levels of c-miRNAs (miR-1, -21, -
23a, -24, -100, -125b, -133a, -206) were analyzed using real-time PCR, and bone 
turnover markers were analyzed by enzyme-linked immunosorbent assay (ELISA). 
Results: There was no significant association between sarcopenia and osteopenia status 
in postmenopausal women. The sarco-osteopenia group had significantly lower body 
weight, jump power, and muscle CSA at 66% of the tibia than the normal and 
xii 
osteopenia groups (p < 0.05). Statistically, there were no significant differences in 
specific c-miRNAs based on sarcopenia and osteoporosis status. However, fold changes 
of miR-21 (FC=2.59) and -23a (FC=2.09) indicated upregulation and miR-125b 
(FC=0.46) indicated downregulation. The relative expression level of miR-125b was 
significantly negatively correlated with age (p < 0.05). The relative expression level of 
miR-21 was significantly negatively correlated with trochanter BMC and cortical 
vBMD at tibia 38% site (p < 0.05). Furthermore, the relative expression level of miR-
23a was significantly positively correlated with TRAP5b levels (p < 0.05). Conclusion: 
There were no statistical differences in target circulating miRNAs (miR-1, -21, -23a, -
24, -100, -125b, -133a, -206) based on bone and muscle status in postmenopausal 
women. However, fold changes of circulating miR-21, -23a, -125b indicated biological 














Chapter 1 Introduction  
Medical, social, and economic advances over diseases have dramatically 
increased life expectancy in the last century. Life expectancy in the U.S. now 
approaches 79 years of age, and in several other countries has exceeded 80 yr (89). As 
people are living longer and healthier, the entire society shifts towards an older 
population. The  population of individuals over the age of 65 is projected to increase 
from 524 million in 2010 to approximately 1 billion by 2030 and 1.5 billion in 2050 
(89). In the U.S., as baby boomers turn 65 years old by the year 2032, there will be 
more people over the age of 65 than children under the age of 15 (54). The term “oldest 
old” is defined as people 85 years and older, currently accounting for 8% of all older 
adults (≥ 65 yr) in the world and 14% of the older population (≥ 65 yr) in the U.S. (89). 
The oldest old now is growing fast in many countries, and is projected to increase at 
least 3 fold from 2010 to 2050 globally (89).  
Global aging presents challenges, such as increased prevalence of chronic 
diseases and disability over time. Muscle fiber number begins to decrease after the age 
of middle 20’s, leading to approximately 50% decline in skeletal muscle mass from 
ages 20 to 80 (39). In the process of aging, bone mineral content is lost gradually, and 
bone loss is accelerated during the menopausal period in women, with a loss of about 
20-30% trabecular bone and 5-10% cortical bone (67). The age-related muscle loss is 
defined as sarcopenia, and bone loss is osteopenia or osteoporosis. The National 
Osteoporosis Foundation in 2014 estimated that over 10 million Americans had 
osteoporosis and an additional 43 million had osteopenia, with the majority of patients 
being older adults (22). Both sarcopenia and osteoporosis are associated with functional 
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impairment and disability or overall frailty, which decreases the quality of life and 
requires long-term care (90). 
Currently, bone mineral density (BMD) measured by dual energy x-ray 
absorptiometry (DXA) is the gold standard for osteoporosis diagnosis based on the 
definition by World Health Organization (WHO). BMD decreases progressively with 
aging, and it is well documented that a one standard deviation (SD) decrease in BMD is 
associated with 1.5-2.6 fold increase of risk of fracture (77). The process of bone 
metabolism is called bone turnover and it consists of two opposite activities: bone 
formation and bone resorption. Bone turnover markers (BTMs) are enzymes (e.g. acid 
phosphatase) reflecting bone metabolic activity or bone matrix degradation products 
released into the circulation during bone resorption (76). Clinically, serum N-terminal 
propeptide of type I procollagen (PINP) and C-terminal cross-linking telopeptide of 
type I collagen (CTX) are proposed to be the referent markers of bone formation and 
resorption, respectively, to predict the risk of fracture or monitor osteoporosis treatment 
(131). PINP is a product of the cleavage of type I procollagen molecules, and CTX is 
derived from the breakdown of type I collagen (111). Another widely used bone 
resorption maker, tartrate-resistant acid phosphatase 5b (TRAP5b), is the enzyme 
representing the metabolic activity of osteoclasts. During menopausal transition, levels 
of BTMs are elevated remarkably, particularly the bone resorption markers, indicating 
accelerated bone loss in postmenopausal women (111). 
Fracture risk increases exponentially with age. Fragility fracture is a major 
contributor to health care costs and the societal burden as worldwide increase of aging 
population. Large cohort studies show that nearly one of two women and one of five 
3 
men aged 50 years and older will have a fracture over the rest of their lifetime, and over 
two thirds of all fractures affect women over the age of 65 (25, 34, 130). Vertebral 
fracture causes back pain and reduces physical function, with prevalence of 25-50% in 
women aged over 50, although only 30% of them are clinically recognized (34). Hip 
fracture is common and known to be associated with increased mortality and disability. 
In the U.S., the lifetime risk of hip fracture is estimated to be 17% for Caucasian 
women and 6% for Caucasian men (25). Current prevention of fractures in the elderly 
mainly depends on the diagnosis of osteoporosis (88). However, sarcopenia, poor 
balance and other non-skeletal factors such as falls, for example, 90% of hip fractures 
occur after a simple fall, increase the risk of fracture with advanced aging, which may 
also lead to the clinical consequence of fractures (61).  
MicroRNAs (miRNAs), short non-coding RNA molecules that regulate 
posttranscriptional gene expression, were discovered two decades ago with over 2,800 
miRNAs in human having been identified to date. The initial research on miRNAs has 
focused primarily at the tissue level, and is found to be related to diseases, such as 
cancer, cardiovascular diseases, and Alzheimer’s diseases. Recent research has found 
some miRNAs, such as miR-1, -133, and -206, are abundant specifically in muscle, 
whereas some other miRNAs regulate osteogenesis and are associated with bone 
diseases, such as osteoporosis and arthritis (74, 84, 117). Mature miRNAs are found to 
be stable in human body fluids such as plasma, and they protect themselves from 
cleavage by endogenous ribonuclease (RNase) activity (7, 70). This suggests that 
circulating miRNAs (c-miRNAs) may be used as potential biomarkers for diagnosis and 
treatment of diseases. For example, serum levels of miR-141 have allowed researchers 
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to distinguish between prostate cancer patients and healthy controls (81), whereas 
circulating miR-21 has been consistently found to be upregulated in patients with 
osteoporotic fractures (91, 116). However, the roles of c-miRNAs in osteoporosis, 
fractures and aging muscles are not fully understood.  
To date, the relationship between c-miRNAs and bone status and subsequent 
risk of fractures remains to be established. Given that current bone turnover markers are 
mainly derived from the synthesis and degradation of type I collagen from bone matrix, 
bone turnover could be assessed by the measurement of bone-specific c-miRNAs that 
reflect bone resorption and formation. In addition, little is known regarding the role of 
skeletal muscle-specific c-miRNAs in sarcopenia in aging. Given that muscle-specific 
miRNAs regulate pathways, such as insulin-like growth factor-1 (IGF-1)/mammalian 
target of rapamycin (mTOR), it is possible that they may be associated with muscle loss 
in aging (68). Finally, given that bone and muscles are connected in 
mechanotransduction and metabolic signaling, and both osteoporosis and sarcopenia are 
key contributors to fractures, it is necessary to include sarcopenia status in fracture risk 
model. Therefore, the purpose of this study was to identify specific c-miRNAs that are 
associated with bone and muscle status in postmenopausal women (60-85 years) and to 
evaluate the use of these c-miRNAs as biomarkers of osteoporosis and sarcopenia.  
Research Questions  
The specific research questions of this study were as follows. 
1. Are there significant differences (upregulation/downregulation) in bone-specific c-
miRNAs (miR-21, -23a, -24, -100, and -125b) in postmenopausal women with and 
without osteoporosis?  
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2. What are the relationships between these bone-specific miRNAs and bone mass, 
bone strength? 
3. Are there significant differences (upregulation/downregulation) in skeletal muscle-
specific c-miRNAs (miR-1, -133, and -206) in postmenopausal women with and 
without sarcopenia?  
4. What are the relationships between these muscle-specific miRNAs and muscle 
mass, muscle strength, and muscle power? 
Hypotheses 
1. I hypothesized that bone-specific c-miRNAs would be upregulated in osteoporotic 
women based on target genes that had been identified or predicted from in vitro or 
animal studies.  
2. I hypothesized that these bone-specific miRNAs would be associated with lower 
bone mass and lower bone strength.  
3. I hypothesized that skeletal muscle-specific c-miRNAs would be upregulated in 
sarcopenic women based on target genes that had been identified or predicted. 
4. I hypothesized that these skeletal muscle-specific miRNAs would be negatively 
associated with muscle mass, muscular strength and power. 
Sub Questions 




1. I hypothesized that bone resorption markers CTX and TRAP5b would be positively 
associated with miRNAs that inhibit osteoblastogenesis (e.g. miR-23a, miR-100) or 
stimulate osteoclastogenesis (e.g. miR-21), whereas the bone formation marker 
PINP would be negatively associated with these miRNAs in postmenopausal 
women. 
Significance of the Study 
Research on miRNAs is fairly new, thus it opens up exciting possibilities for 
novel diagnosis and treatment of diseases. The measurement of c-miRNAs may serve as 
potential biomarkers of diseases of bone and skeletal muscle as well as risk of fractures. 
However, c-miRNAs that regulate bone and muscle metabolism are not fully identified 
and the role of miRNAs in aging is not known in depth. The measurement of serum 
miRNAs is novel, and it reflects the regulation of gene expression, thus providing the 
underlying cellular and molecular process involved in bone turnover and muscle aging. 
Therefore, the significance of this study is to identify c-miRNAs in postmenopausal 
women with osteoporosis and sarcopenia to help develop new and reliable serum 
markers of fragility, which would be a great progression in clinical diagnoses of aging- 
related diseases.  
Assumptions 
1. Participants honestly and accurately completed all the questionnaires. 
2. Questionnaires used in this study were valid and reliable for use in this population. 
3. Participants accurately followed the instruction of fasting for at least 8 hours prior to 
blood draw. 
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4. miRNAs in the blood samples were not degraded during storage in -80°C freezer.  
Delimitations 
1. The findings of this study only apply to community-dwelling postmenopausal 
women ages 60-85 years. 
2. Participants were recruited from Norman and Oklahoma City, Oklahoma areas. 
3. Individuals with metal implants at hip or spine were excluded from the study.   
Limitations 
1. Participants were volunteers and thus may not be truly representative of the 
population. 
2. Measurements only applied to the selected five bone- specific (miR-21, -23a, -24, -
100, and -125b) and three muscle-specific (miR-1, -133, and -206) miRNAs. 
3. Participants were limited to 350 lbs and 6’4’’ due to DXA machine capacity.  
4. History of hormone replacement therapy or seasonal variation were not controlled. 
Operational Definitions 
1. Appendicular Skeletal Muscle Mass (ASM, kg): Fat-free lean mass at arms and legs 
(9). 
2. Areal Bone Mineral Density (aBMD, g/cm2): The amount of bone mineral per unit of 
two-dimensional projected area (76). 
3. Argonaute (AGO) family proteins: Proteins that associate with small RNAs and 
function as effectors in RNA silencing (49). 
4. Bone Morphogenetic Proteins (BMPs): A group of growth factors that are able to 
induce endochondral bone formation (76). 
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5. Bone formation: The building of new bone by osteoblasts (76). 
6. Bone Mineral Content (BMC, mg): also called bone mass; the amount of mineral 
mass measured in a bone, bony area, or the body in grams (76). 
7. Bone Strength Index (BSI, mm3): The density weighed polar section modulus of given 
bone cross-section. It gives a measure of compressive bone strength at the metaphysis 
(120). 
8. Bone turnover: The amount of bone or the fraction of it that is replaced by new bone 
(76).  
9. Bone turnover markers (BTMs): Enzymes (e.g. acid phosphatase) reflecting bone 
metabolic activity or bone matrix degradation products released into the circulation 
during bone resorption (76).  
10. Bone resorption: The breakdown of bone tissue by osteoclasts (76).  
11. Cortical bone: Dense, compact bone that is 80-90% calcified and fulfills mainly 
mechanical and protective functions for the body, such as the shafts of the long bones 
of the arms and legs (76).  
12. Complementary DNA (cDNA): A double-stranded DNA synthesized from a mRNA 
template using reverse transcriptase (12). 
13. C-telopeptide of Type I collagen cross-links (CTX): A bone resorption marker that 
can be measured in the serum to determine the degradation of products of type I 
collagen (76). 
14. Endogenous Control: A molecule that is present in the RNA or DNA sample which 
is stable across multiple samples (12).  
15. Falls: Unintentionally comes to rest on the ground, floor, or other lower level (137). 
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16. Menopause: Cessation of menstruation, usually occurs at 48-50 years of age in 
healthy women (111).  
17. MicroRNA (miRNA): Short, non-coding, single-stranded RNA molecules made of 
20-24 nucleotides that negatively regulate protein expression (74).  
18. Osteoblast: Bone cell responsible for bone formation (76). 
19. Osteoclast: Bone cell responsible for bone resorption (76). 
20. Osteocyte: A mature bone cell, formed when an osteoblast is embedded in bone 
matrix it has secreted, composing 90-95% of all bone cells (76).  
21. Osteopenia: BMD T-score that is less than -1 and greater than -2.5 SD compared to 
the young adult reference value (88, 94). 
22. Osteoporosis: BMD T-score more than 2.5 SD below the young adult reference 
value. Bone is fragile, and bone fracture risk is increased (88, 94). 
23. Peripheral Quantitative Computed Tomography (pQCT): Peripheral QCT, an 
equipment with a lower cost and lower radiation exposure for measuring cortical 
and trabecular volumetric BMD (vBMD), bone geometry and SSI, which can give a 
true description of the cross-sectional geometry and bone composition in contrast to 
the planar description via DXA (120). 
24. Periosteal circumference: An important indicator of bone size and closely related to 
bone strength. It can be directly determined through pQCT (120). 
25. N-terminal propeptide of type I procollagen (PINP): A bone formation marker that is 
derived from the cleavage of type I procollagen molecules (76).  
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26. Real-time polymerase chain reaction (RT-q-PCR): A laboratory technique of 
molecular biology based on PCR, which monitors the amplification of a targeted 
DNA or cDNA molecule during the PCR in real-time.  
27. Receptor activator of nuclear factor kappa-B ligand (RANKL): A type II membrane 
protein that is known to stimulate osteoclast formation and activity (16) 
28. Runt-related transcription factor 2 (RUNX2): A protein that is encoded by the 
RUNX2 gene in humans and associated with osteoblast differentiation (76).  
29. Sarcopenia: Skeletal muscle mass index more than 2 standard deviations below the 
reference population (9).  
30. Skeletal Muscle Mass Index (SMI, kg/m2): appendicular lean muscle mass (kg) 
divided by height squared (m2). 
31. Stress Strain Index (SSI, mm3): A cortical density weighed section modulus of the 
bone. It gives a measure of bending and torsional strength of diaphyseal sites.  
32. T-score: Standard deviation units in relation to the average of healthy Caucasian 
young females. 
33. Threshold Cycle (Ct): In real-time PCR, the number of cycles required for the 
fluorescent signal to cross the threshold (i.e. background level) (12). 
34. Trabecular bone: also called cancellous bone; spongy bone enclosing spaces filled 
with bone marrow, blood vessels and connective tissue, and is only 10-20% calcified. 
It fulfills primarily metabolic functions for the body (76). 
35. Volumetric Bone Mineral Density (vBMD, g/cm3): The BMC per cross-sectional area 
of a bone (99). 
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36. Wnt signals: a family of signaling proteins that participate in mitogenic stimulation, 
cell fate specification, and differentiation, including the canonical Wnt pathway and 
the noncanonical Wnt pathway (76). 
37. Z-score: standard deviation units above or below what is normally expected for an 
individual of the same age, sex, weight, and ethnic or racial origin.  
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Chapter 2 Review of Literature 
Introduction 
The world is aging. Aging is accompanied with body composition changes, 
functional decline, and age-related diseases, such as osteoporosis and sarcopenia. 
Osteoporosis is a prevalent public health disease without overt symptoms, and patients 
typically come to clinical attention only after suffering a fracture. Sarcopenia, the age-
related loss of muscle mass and function, increases the risk of mortality and decreases 
quality of life. It is widely supported that fractures are related to low bone mineral 
density (BMD), while fractures also occur as a result of falls. Therefore, both 
osteoporosis and sarcopenia contribute to fracture risk. Bone and muscle are closely 
linked, thus it becomes more evident that in addition to measuring BMD, other non-
skeletal risk factors are important to predict risk of fracture and severity of osteoporosis. 
MicroRNAs (miRNAs), discovered two decades ago, are short non-coding, 
single-stranded RNA molecules, 20-24 nucleotides (nt) in length that negatively 
regulate posttranscriptional protein expression. So far, 2588 (miRBase.org) miRNAs 
have been identified in humans and 1881 of them have been fully sequenced (46). A 
single miRNA may target multiple genes, and miRNAs in humans may have a direct 
influence on at least 30% of genes in the human genome according to computer model. 
It is well studied and documented that miRNAs are associated with cancer and 
cardiovascular diseases (81, 100). Some miRNAs have been identified to regulate 
muscle synthesis and bone osteogenesis, but their roles in osteoporosis and sarcopenia 
are not established. The purpose of this review is to examine current findings on the 
prevalence of osteoporosis and sarcopenia in aging, and the role of miRNAs in 
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osteoporosis and sarcopenia in aging populations. The literature is presented in the 
following sections: 1. Age-related Bone Loss, 2. Osteoporosis Diagnosis and 
Intervention, 3. Age-related Changes in Skeletal Muscle, 4. Fracture Prevention, 5. 
miRNAs in Bone and Muscle.  
Age-related Bone Loss 
After reaching peak bone mass during 20-30 years in adults, BMD starts to 
progressively decline, which has been observed in numerous population based studies 
(32, 51, 52, 105). Riggs et al. (105) measured BMD at radius and lumbar spine in 
healthy Caucasian women aged 20-88 yr (n=139, mean 52 yr) using single and dual 
photon absorptiometry, and the measurements were repeated 2-6 times during 0.8-3.4 
yrs follow-up. They found that BMD at radius remained stable before menopause but 
significantly declined by 1.01% per year after menopause. BMD at lumbar spine 
decreased 1.32% per year before menopause and 0.97% per year after menopause. The 
Framingham osteoporosis study measured BMD at the femur and radius using Lunar 
SP2 and DP3 absorptiometry in older participants (n=1102, mean age 76 yr) in the late 
1980s. Hannan et al. (51)  found that BMD at both sites significantly decreased with 
aging at similar rates for both sexes, even after adjusting for height and weight. After a 
4-year of follow-up, Hannan et al. (52) reported that women lost BMD at 1.2% per year 
at the radius and 0.86% per year at the femoral trochanter whereas men lost 0.9% per 
year and 0.04% per year, respectively. The study of osteoporotic fractures by Ensrud et 
al. (32) measured BMD at total hip using DXA and calcaneus (heel) using single photon 
absorptiometry in Caucasian women over 65 yr (n=5698). They found that bone loss 
increased with aging at both sites. At the total hip, the rate of decline in BMD in those 
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subjects over 85 yr was up to 4-fold greater than those 67-69 yr. Unsurprisingly, 
hormone replacement therapy users had a slower rate of bone loss compared to 
nonusers at equivalent ages.  
BMD in most studies was measured by DXA. However, DXA measurements are 
two dimensional, and thus cannot distinguish cortical and trabecular bones, or measure 
bone microarchitecture or strength. Another technology, central quantitative computed 
tomography (QCT) or peripheral QCT (pQCT), provides noninvasive measurement to 
evaluate bone “quality” in vivo. Riggs et al. (102) measured trabecular vBMD at lumbar 
spine by QCT (Light Speed QX-I/Ultra) and trabecular and cortical vBMDs at distal 
radius and tibia by pQCT (Densiscan 1000) in participants aged 20-97 years (n=553) at 
baseline and after a 3-year of follow-up. They found that the loss of trabecular vBMD 
began in young adulthood and was independent of sex steroid levels, whereas cortical 
bone loss did not begin until middle or even older ages and was associated with sex 
steroid deficiency. The loss of trabecular bone was greater in the lumbar spine as 
compared to the peripheral sites, and women generally had greater bone loss than men, 
particularly during menopause transition. On average, women lost about 1.6% of 
trabecular vBMD each year at lumbar spine before age 50 and 2.6% after age 50, 
whereas men lost about 0.84% and 1.85% before and after age 50, respectively. This 
means that, accumulatively, women lost 37% of trabecular bone and 6% of cortical 
bone before age 50 compared to 42% and 15% of each after age 50. Another study by 
Riggs et al. (104) estimated that women could lose as much as 55% of trabecular vBMD 
over their lifespan, which was significantly higher than the loss of 46% in men, 
especially considering that women had a lower bone mass than men.  
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Several mechanisms are involved in age-related bone loss, including oxidative 
stress, sex steroids deficiency, and apoptosis. (56). Intracellular metabolism generates 
reactive oxygen species (ROS), such as superoxide anions (O2
-), hydroxyl radicals  
(HO-), and hydrogen peroxide (H2O2). As aging, the antioxidant system is impaired, 
such as the ROS-scavenging enzyme superoxide dismutase (SOD), resulting in 
accumulation of ROS and further increasing oxidative stress. In a mouse model of SOD 
deficiency, the SOD knockout mice have a higher level of oxidative stress, reduced 
BMD and bone strength, and a higher rate of apoptosis, resulting in fewer osteoblasts 
than in wild-type mice (87, 122). In addition, the accumulation of ROS causes retention 
of the forkhead box O (FoxO) family of transcription factors in the nucleus and elevated 
p66Shc signaling activity, both of which lead to reduced bone formation and age-related 
bone loss (4, 86).  
Sex steroids play a critical role in regulating bone turnover rate. During 
menopausal transition, serum estradiol levels decrease by 85-90% (66), bone resorption 
increases by 90%, whereas bone formation only increases by 45% (40). The net 
imbalance in bone formation and resorption results in rapid bone loss, particularly in 
trabecular bone (40, 103). Estrogen stimulates differentiation of bone marrow stromal 
cells to the osteoblast lineage as well as differentiation of preosteoblasts to osteoblasts. 
In addition, estrogen inhibits osteoblast and osteocyte apoptosis but stimulates the 
osteoblastic production of growth factors, such as insulin like factor-1(IGF-1), 
transforming growth factor-β (TGF-β), as well as procollagen synthesis (33, 98). Age-
related estrogen deficiency is linked to a significant increase in stromal cell 
differentiation into fat lineage and greater marrow adiposity, which leads to fewer 
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stromal cells differentiating into osteoblast lineage (83). More recently, it has been 
discovered that estrogen inhibits serum levels of sclerostin, a potent inhibitor of the Wnt 
signaling pathway, thus maintaining bone formation (80, 82). Estrogen also regulates 
osteoclast development effectively by inhibiting production of the receptor activator of 
nuclear factor kappa-B ligand (RANKL) by bone marrow stromal or osteoblast 
precursor cells (T & B cells), and stimulating production of osteoprotegerin (OPG, 
RANKL decoy receptor) by osteoblast lineage cells to limit exposure of osteoclast 
lineage cells to RANKL (65). In postmenopausal women, the dramatic decline in 
estrogen levels alters the relative RANKL/OPG ratio, resulting in elevated osteoclast 
development and activity.  
Bone loss is more pronounced in trabecular than cortical bone for two reasons: 
1) trabecular bone loss begins in young adulthood, and 2) trabecular components have a 
greater surface area where bone resorption occurs (103). Women have rapid trabecular 
bone loss as well as overall bone loss during the menopausal transition compared to 
men at corresponding ages (67). The significant changes in trabecular microarchitecture 
are related to decline in bone strength and ultimately increase fracture risks in 
postmenopausal women. This leads to fractures commonly occurring in trabecular-rich 
regions, such as distal forearms and vertebrae, particularly in females during early 
menopause.  
Osteoporosis Diagnosis and Intervention 
Although the term “osteoporosis” was originally used by French pathologist and 
surgeon Jean Lobstein in 1835, the first international consensus of a conceptual 
definition of osteoporosis was achieved in 1993, stating that “osteoporosis is a systemic 
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skeletal disease characterized by low bone mass and microarchitectural deterioration of 
bone tissue with a consequent increase in bone fragility and susceptibility to fracture” 
(94). In 1994, the World Health Organization (WHO) proposed using BMD as the 
diagnostic criterion for osteoporosis. BMD values more than 2.5 standard deviations 
(SD) below the mean of a young reference population (T-score ≤ -2.5) were deemed to 
indicate a 20% risk of a major fracture within 10 years (88). Later, guidelines were 
updated using femoral neck measurements instead of multiple sites for BMD (60). The 
Third National Health and Nutritional Examination Survey (NHANES III) database for 
femoral neck measurements in Caucasian women aged 20-29 years were used as the 
reference population. Over the past two decades, diagnosis and assessment of 
osteoporosis have been updated several times (62, 75). In 2001, the National Institutes 
of Health Consensus Development Panel on Osteoporosis updated the definition of 
osteoporosis, defining it as “a skeletal disorder characterized by compromised bone 
strength predisposing a person to an increased risk of fracture”, and this definition is 
still valid and useful to this day (97).  
Conventionally, a BMD T-score ≤ -2.5 at the lumbar spine or hip is used as the 
intervention threshold of osteoporosis. It is reported that age-adjusted risk of hip 
fracture increased 2.6 fold with every SD decrease in hip BMD (77). However, this 
fracture risk model disassociates bone strength from diagnosis, and a significant 
proportion of fragility fractures occur in individuals with a BMD T-score above -2.5. In 
fact, approximately 50% of hip fractures occur in individuals without osteoporosis 
(133). In addition, a given T-score of -2.5 has different impact on fracture probabilities 
throughout the lifespan. For example, the 10-year probability of fracture is consistently 
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higher in women with osteoporosis (T-score ≤ -2.5) than those without osteoporosis (T-
score > -2.5). However, the difference between categories decreases after age 65 and 
individuals with osteoporosis have an even lower rate of fracture than those without 
osteoporosis after age 78 (61). Furthermore, fracture rates vary from country to country. 
For example, at a given 10-year probability of major fracture of 20%, the BMD T-score 
is -2.5 in the US, whereas it is approximately -2.0 in Iceland and -4.5 in Venezuela (75). 
Therefore, the use of BMD is not completely appropriate to all populations as an 
intervention threshold. A better intervention threshold is needed for diagnosis and 
treatment to reduce healthcare costs and improve quality of life for those suffering from 
this disease. 
Age-related Changes in Skeletal Muscle 
Aging is accompanied with declines in muscle mass and strength, and this 
phenomenon has captured researchers’ attention in the recent 30 years. In 1989, Irwin 
Rosenberg pointed out the importance of age-related decline in lean body mass and 
coined the term “sarcopenia” to describe it (112). Sarco-, from Greek, means “flesh”, 
and -penia indicates “loss”. Thus, sarcopenia means loss of skeletal muscle mass. 
Recently, studies have identified the disconnection between loss of muscle mass and 
muscle strength in the conventional definition of sarcopenia, thus incorporating muscle 
strength and physical performance into sarcopenia criteria (23, 27, 37, 45, 125). Since 
2009, several consensus operational criteria have been proposed to define sarcopenia, 
including: the International Working Group (IWG) (2009), the European Working 
Group on Sarcopenia in Older People (EWGSOP) (2010), the Foundation for the 
National Institutes of Health (FNIH) (2014), and Asian Working Group for Sarcopenia 
19 
(AWGS) (2014). According to the EWGSOP, sarcopenia is a syndrome characterized 
by progressive and generalized loss of skeletal muscle mass and strength with a risk of 
adverse outcomes such as physical disability, poor quality of life and death (23).  
Several mechanisms are involved in the development of sarcopenia. At the 
cellular level, there is substantial loss of both muscle fiber size (cross-sectional area) 
and number, especially the shrinkage of type II fibers. Muscle twitches become smaller 
and slower due to impaired calcium release (35). Meanwhile, connective tissue content 
increases within and between fibers, which is also called fat infiltration of muscle. At 
the metabolic level, key factors of regulating protein balance, such as IGF-1 and mTOR 
kinase, are decreased (95). At the vascular level, capillary density is decreased due to 
increased oxidative stress and mitochondrial dysfunction. Inflammatory factors, such as 
tumor necrosis factor alpha (TNF-α), interleukin 9 (IL-6), and C-reactive protein (CRP), 
are increased (71, 95). All these factors contribute to the development of sarcopenia. 
Exercise intervention and protein supplementation have the potential to prevent or delay 
the development of sarcopenia by increasing growth to reach peak muscle mass and 
strength and simultaneously slowing down age-related decline (28, 95). Although 
estrogen plays a critical role in osteoblast/osteoclast biology, the effects of estrogen on 
skeletal metabolism at the cellular and molecular level remains unresolved.  
Due to two operational definitions of sarcopenia, two approaches have been 
used to diagnose sarcopenia in research. Initially, sarcopenia is classified based on 
muscle mass alone using the skeletal muscle mass index (SMI), which equals to 
appendicular skeletal muscle mass (ASM)/ height2 (m2). Sarcopenia is defined as an 
SMI that is 2 SD below the average of the young reference population (9). Based on this 
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conventional definition, the prevalence of sarcopenia ranges 13-24% among individuals 
under 70 years and >50% among those over 80 years when compared to a young 
reference group (9). More recently, the EWGSOP and FNIH suggest combining low 
muscle mass with either low muscle strength or poor physical performance to diagnose 
sarcopenia, whereas the IWG recommends combining low muscle mass with low 
muscle function (23, 37).  
Patel et al. (92) measured body composition and physical performance in 103 
community-dwelling UK men with an average age of 73 yr. They found that the 
prevalence of sarcopenia in older people in the UK was 6.8% in men using the 
EWGSOP definition. Patil et al. (93) studied 70-80 year old community-dwelling 
women in Finland (n=409), and found the prevalence of sarcopenia was 0.9% using the 
EWGSOP definition compared to 2.7% using the IWG definition The International 
Sarcopenia Initiative (2014) reviewed global studies using the EWGSOP definition of 
sarcopenia and reported that the prevalence of sarcopenia ranged from 1 to 29% in 
community-dwelling elderly, approximately 10% in the acute hospital-care population, 
and increased to 14-33% in the long-term care population (24). Generally, the 
prevalence of sarcopenia is higher in women than men. 
The loss of muscle strength is much faster than the loss of muscle mass in the 
process of aging (45). Grip strength has been widely accepted as the most practical 
method of measuring muscle strength in a clinical setting. It is an easy and inexpensive 
screening tool and has been found to correlate with incident disability for activity of 
daily life (ADL) (2, 42). The cutoffs from EWGSOP for grip strength are 30 kg for men 
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and 20 kg for women, whereas 26 kg for men and 16 kg for women are used to define 
weakness in FNIH’s definition and in AWGS (21, 23, 27).  
Gait speed is the most common measure of lower extremity performance in 
clinical setting and for epidemiological sarcopenia studies. Since it is reliable, valid, and 
correlates with physical performance, it is known as an “almost perfect measure” and 
“the sixth vital sign” (38). Gait speed is a strong predictor of health status and adverse 
outcomes, and can be used as a single tool to replace the complete set of the Short 
Physical Performance Battery (SPPB) (48, 128). It can be quickly and accurately 
assessed by measuring the time taken to walk a given distance, such as 4 m, at a normal 
pace. The EWGSOP utilizes 0.8 m/s to define functional deficiency, whereas the IWG 
uses 1.0 m/s as the cutoff.  
Recently, more studies have begun to measure muscle power to examine 
functional changes as a new component of sarcopenia (18). Rittweger et al. (106) 
assessed jump power through jumping mechanography from participants aged 24-88 
years and found that jump power had good test-retest reliability, and was particularly 
useful in middle-age to older participants. Buehring et al. (18) found that jumping 
power correlated with grip strength, with an even stronger correlation with age in 
elderly participants over 70 years of age, thus concluding that jump power could 
potentially detect changes in muscle function and better monitor sarcopenia. Singh et al. 
(121) found community-dwelling individuals, aged 55-75 years, classified as sarcopenia 
using the conventional definition had significantly lower jump power but not muscle 
strength compared to non-sarcopenia individuals. Bean et al. (2003) analyzed the 
population based cohort InCHIANTI study (n=1032, mean 74.2 yr), and found poor 
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muscle power in legs measured by knee extension was more associated with poor 
mobility (gait speed < 0.8 m/s) than leg strength.  
Currently, one of the most challenging issues is the lack of consensus about the 
clinical definition of sarcopenia and assessment of muscle function and muscle strength 
among consensus groups and studies. Due to different criteria used for diagnosis, the 
prevalence of sarcopenia varies greatly, which may lead to different conclusions and 
implications for treatment. Bischoff-Ferrari et al. (13) compared the current seven 
available definitions of sarcopenia using the original Boston cohort, which included 445 
community-dwelling older adults over 65 years of age with a 3 year follow-up. They 
reported that the prevalence of sarcopenia decreased from 11% to 7% when using the 
EWGSOP definition instead of the conventional one. The elderly with sarcopenia based 
on the conventional and the EWGSOP definitions had the highest possibility of falls 
compared to the non-sarcopenia ones, with odds ratio of 1.54 and 1.82, respectively, 
thus suggesting that these two definitions were the best to recognize the risk of falls 
among sarcopenic elderly.  
Fracture Prevention 
Fracture is the primary clinical end point for osteoporosis treatment. The risk of 
fracture increases remarkably with age, with more than two thirds of fractures occurring 
in women over 65 years old. Vertebral and hip fractures are the major osteoporotic 
fractures that have high morbidity and mortality and societal burden, and they are most 
common in postmenopausal women due to pronounced decline of estrogen. Vertebral 
fractures are common, with a prevalence of 25-50% in women over 50 years of age and 
particularly high over 75 years old, leading to back pain and reduced physical function, 
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but only 30% of them are clinically recognized. Hip fractures are associated with 8.4% 
to 36% mortality in the first year after fracture (1).  
It is well established that the risk of fractures is about four-fold higher in 
osteoporotic patients compared to individuals with normal BMD. However, fractures 
are not only associated with bone loss, or the degree of trauma. In the US cohort Study 
of Osteoporotic Fractures (124), BMD of community-dwelling women aged 65 and 
older (n=9704) were measured at baseline, and participants were contacted every 4 
months via phone or mail to record all types of fractures with at least 8 years of follow-
ups. The researchers found that only 15% of all types of fractures were attributable to 
osteoporosis, although women with low BMD have higher prevalence of all types of 
fractures. Osteoporosis at spine or hip contributed to 8% to 44% of fractures, and the 
relationship between BMD and fractures in women over 65 years old was moderate 
(124). Another epidemiology study in England and Wales investigated the age and 
gender specific prevalence of fractures in a sample of general practice research 
database. It was found that the relative risk of hip fracture in elderly people aged 60-80 
years increased 13 fold whereas only two fold increased risk was due to aging (130). 
Therefore, it is apparent that not only bone loss but also other factors contribute to the 
increased fracture risk with advancing age. Vertebral fractures are associated with 
decreased BMD and deteriorated bone microarchitecture that are not related to 
menopause, and they are a stronger fracture predictor than low BMD or other fractures 
(14). Besides osteoporosis, additional interventions are needed to find effective 
prevention strategies for fractures, such as fall prevention and other fracture risk factors. 
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A major non-skeletal factor that contributes to fracture risk is falls. Falls are 
defined as “unintentionally coming to rest on the ground, floor, or other lower level” 
(137). Although most falls do not result in fractures, over 90% of all fractures occur 
after a fall. Therefore, fall prevention is the key to prevent fractures. Hip fractures tend 
to occur in less active people, whereas forearm and humerus fractures are more 
common among people who are more active. Patients with osteoarthritis, particularly at 
weight-bearing joints, have a higher risk of fractures due to falls, although they have 
higher bone density compared to those without osteoarthritis. Risk factors of falls are: 
gait instability, weakness, visual/cognitive impairment, home hazards and 
circumstances (e.g. snow, ice), and side effects from drugs (e.g. antidepressants, 
anticonvulsants) (111).  
Gait instability, the major intrinsic risk factor of falls, is often due to muscle 
weakness, or sarcopenia. Weaker muscle decreases muscle strength and power, impairs 
physical performance, leading to increases in falls and fractures. Much the same as 
osteoporosis predicting risk of bone fractures, sarcopenia is associated with increased 
risk of falls, which consequently increases fractures, disability, and mortality (108). 
Therefore, sarcopenia should be the next focus in fracture prevention. 
Bone and skeletal muscle are two fundamental systems in the human body that 
interact with each other. Mechanically, muscle attaches to bone and generates 
mechanical loading on bone during muscle contraction. This mechanotransduction 
seems to regulate both skeletal muscle and bone metabolism (44). Moreover, there is 
accumulating evidence that bone and muscle are regulated by several signaling 
pathways that affect both in growth, diseases and aging. For instance, BMP signaling 
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not only regulates osteoblasts and osteoclasts to maintain bone homeostasis, but also 
plays a role in myogenesis and skeletal muscle mass (114, 115). Vitamin D is also a key 
regulator in bone remodeling process and calcium and phosphate homeostasis. 
Recently, research revealed that vitamin D receptor is also expressed in skeletal muscle 
and low vitamin D levels are associated with increased risk of falls in the elderly (47). 
IGF-1, which is important in muscle hypertrophy, also was found to stimulate osteoblast 
differentiation and bone formation (10). Similarly, mTORC1, a major regulator of 
protein synthesis, might also be a potential regulator in bone (44). Osteocalcin, 
exclusively secreted by osteoblasts to regulate bone mineralization and maintain 
calcium homeostasis, also has receptors in the skeletal muscle indicating that it might 
have an effect on muscle strength as well. It is well known that Wnt signaling plays an 
important role in bone development and homeostasis, however, recent research also 
found it might be related to myogenesis in skeletal muscle (113). Overall, bone and 
muscle are two connected tissues with mechanical and metabolic interactions. 
Therefore, it is important to recognize the connection between osteoporosis and 
sarcopenia and the role of sarcopenia in fracture prevention. 
Numerous studies have shown that exercise improves BMD, muscle strength 
and functional performance in community-dwelling older adults, which further reduces 
falls as well as the risk of fractures (63, 85, 119, 138). Even unsupervised home 
exercise programs reduce falls, however, it is better to have an exercise program that 
involves strength and balance training. In a study by Nelson et al. (85), the first 
resistance training study on bone density two decades ago, postmenopausal women 
aged 50-70 were randomly assigned to a one year high intensity resistance training 
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group (n=20, exercise twice per week, 5 exercises) or control group (n=20). The 
researchers found that the resistance training group significantly increased their femoral 
neck and lumbar spine BMD after a year of training, whereas the control group had 
significant bone loss after one year. Meanwhile, muscle strength and balance were 
improved in the resistance training group but decreased in the controls, compared to 
their baseline. Zhao et al. (138) conducted a meta-analysis to investigate the effects of 
resistance exercise (≥ 6 months) on BMD in postmenopausal women, and effect size 
was estimated using the calculation of standardized mean difference. They found that 
overall resistance training (24 studies, 1769 postmenopausal women) significantly 
improved femoral neck and lumbar spine BMDs with effect sizes of 0.303 and 0.311, 
respectively. However, when comparing the resistance training alone intervention and 
combined resistance and weight-bearing exercise intervention, only the combined 
resistance training intervention significantly increased femoral neck and lumbar spine 
BMD, with effect sizes of 0.411 and 0.431, respectively. In a meta-analysis by Kelly et 
al. (63), they examined the effects of ground and joint impact exercise intervention (≥24 
wk) on BMD in postmenopausal women using the standardized mean difference as 
effect size as well. They reported that ground/joint impact exercise had small but 
significantly beneficial effects on femoral neck and lumbar spine BMDs, with effect 
sizes of 0.288 and 0.179, respectively, which could slightly reduce the risk of 
osteoporotic fracture.  
Kemmler et al. (64) conducted a meta-analysis on the effects of exercise 
(resistance, endurance, balance, etc.) intervention on fracture prevention in the elderly. 
The relative risk (RR) of fractures in each study was calculated. However, the exercise 
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intervention groups were not found to have differences in overall fracture (RR=0.49, 
p=0.28) and vertebral fracture (RR=0.56, p=0.26) compared to the older controls. In 
another meta-analysis by Polidoulis et al. (96), they reviewed six exercise intervention 
studies (5-12 months) in postmenopausal women that measured bone strength by pQCT. 
They reported that lower body exercise significantly improved trabecular vBMD at 
distal tibia and cortical vBMD at tibia shaft, suggesting that exercise may diminish bone 
loss in postmenopausal women.  
Cruz-Jentoft et al. (24) reviewed seven studies that examined the effects of 
exercise intervention on skeletal muscle in older adults. They found that 3-18 months of 
resistance training alone significantly increased muscle mass, strength and functional 
performance, such as gait speed and chair rise. They also reported that overall exercise 
(endurance, resistance, balance) generally improved muscle strength and functional 
performance in community-dwelling older adults. 
MiRNAs in Bone and Muscle 
In 1993, Dr. Victor Ambros discovered the first miRNA, lin-4, which is 
responsible for normal larval development of C. elegans (72). Soon after, Dr. Gary 
Ruvkun’s lab found that lin-4 RNA is complementary to 7 sites in the lin-14 3’UTR, 
thus downregulating the expression of the lin-14 protein (136). In 2000, Dr. Gary 
Ruvkun discovered a second miRNA, let-7, which is conserved across animals, 
including humans, that started the small RNA revolution (101). Since then, the research 
of miRNAs is emerging, and miRNAs are recognized as a distinct class of biological 
regulators in normal gene expression as well as disease.  
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MiRNA genes are transcribed by RNA polymerase II to generate a long, hairpin 
shape termed primary miRNA (pri-miRNA). Then the nuclear ribonuclease III enzyme 
in the nucleus, Drosha, processes the pri-miRNA into a 60-70 nucleotide stem-loop 
structure called precursor miRNA (pre-miRNA). Exported into the cytoplasm by 
exportin-5, the pre-miRNA is processed into an unstable double-stranded miRNA by a 
second ribonuclease III enzyme called Dicer. The miRNA duplex is then incorporated 
into the RNA-induced silencing complex (RISC), which includes an argonaute protein. 
One strand of the pre-miRNA is degraded, while the other strand becomes mature 
miRNA which binds to a complementary site in the 3’ untranslated region (UTR) of the 
target mRNA to destabilize the mRNA or repress translation (74).   
A tissue-specific miRNA is defined as “a mature miRNA that is expressed at 
least 20-fold higher in a specific tissue than the average expression of all other tissues” 
(78). Sempere et al. (117) first identified 3 muscle-specific miRNAs in mice and 
humans: miR-1, -133, and -206, which regulate cardiac and skeletal muscle 
development, and proliferation and differentiation of myoblast. MiR-1 and -133a are 
well established to be highly expressed in cardiac and skeletal muscle, whereas miR-
206 is expressed in skeletal muscle only, primarily in slow twitch fibers (69). 
Additional muscle-specific miRNAs recently identified are: miR-208a, -208b, -486 and 
-499. In particular, miR-208a is specifically found in cardiac muscle. It is reported that 
miR-1 is related to inhibition of myoblast proliferation, which counteracts the 
promotion of proliferation by miR-133a (3).  
McCarthy et al. (79) applied mechanical overload to the plantaris muscle of 
mice for 7 days to induce muscle hypertrophy and analyzed several miRNAs from 
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plantaris muscle tissue. They found that after 7 days of overload, the expression of 
Drosha and Exportin-5 increased by 50%, and the expression of pri-miRNA-1-2, -133a-
2 increased by 2-fold. Although the expression of miR-206 was unchanged, the 
expression of miR-1 and -133a decreased by 50%, which suggested that the overload 
may stimulate the expression of genes known to be related to muscle growth. Elia et al. 
(31) reported that miR-1 targeted IGF-1 pathways in mice model to regulate skeletal 
muscle hypertrophy, as it was partially complimentary to 3’ UTR. Allen et al. (3) 
investigated muscle-specific miRNAs in mice after 12 days of spaceflight. They found 
that miR-206 in gastrocnemius muscle decreased significantly by 50% compared to 
preflight expression levels. Although miR-1 or -133a were not changed, the ratio of 
miR-1 and -133a increased significantly after spaceflight, suggesting potential 
inhibition of cell proliferation.  
Most of the findings mentioned above were based on the analysis of muscle 
tissue in animals and humans. More recently, researchers began to measure c-miRNAs 
in humans as markers of physical fitness, stress responses, risk and status of diseases, 
although results regarding the effects of exercise on muscle-specific c-miRNAs are not 
consistent so far (5). In a study by Baggish et al. (6), 10 participants underwent 90 days 
of rowing training to improve their aerobic capacity. Prior to and post 90 days training, 
peak oxygen consumption (VO2max) was tested via cycle ergometer, and eight miRNAs 
involved in angiogenesis, inflammation, cardiac and skeletal muscle function, and 
hypoxia responses were measured in serum: miR-20, -21, -133a, -146a, -210, -221/-222, 
-328. Compared to resting baseline levels, they found that circulating miR-146a, -222, -
21, and -221 were significantly increased after acute cycling at baseline as well as at 
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rest after 90 days of aerobic training. However, only circulating miR-146a and -222 
after acute cycling were increased post-training, whereas miR-21 and -221 were not 
changed, suggesting a possible maximal ceiling expression of these specific c-miRNAs. 
In addition, they found that miR-146a was significantly positively correlated with 
VO2max (r=0.63), suggesting that serum miR-146a may serve as a quantitative biomarker 
of cardiorespiratory fitness. Banzet et al. (8) measured muscle-specific miRNAs (miR-
1, -133a/b, -208a/b, and 499) and muscle related miRNAs (miR-181 and 214) in nine 
recreationally active and healthy young men in response to a single bout of 30 min 
uphill or downhill walking on treadmill (1 m/s, 25% of grade, 12% of body weight 
loaded backpack). They reported that the levels of circulating miR-1, -133a, -133b and -
208b were significantly elevated 6 hours post downhill walking compared to baseline, 
and no significant changes were overserved in uphill walking. This finding suggested 
that responses of miRNAs were related to exercise mode, with no changes in concentric 
exercises but significant decreases in eccentric exercise. Gomes et al. (43) measured c-
miRNA levels before and after half-marathon, and they reported that circulating miR-1, 
-133a, and -206 were significantly upregulated after a half-marathon run.  
MiRNAs also regulate osteogenesis and are associated with bone diseases such 
as osteoporosis, osteoarthrosis, and rheumatoid arthritis. Bone-regulating miRNAs are 
those expressed in osteoblast lineage cells for regulation of bone formation by either 
direct repression of inhibitors of osteoblast differentiation or by their response to 
osteogenic signals, such as BMP, to promote osteogenesis. More and more miRNAs 
have been identified to regulate osteoblastogenesis and bone formation by targeting 
inhibitors of osteogenesis or osteogenic factors (74). Some miRNAs regulate 
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osteoblastogenesis, such as miR-20a (stimulates BMP/RUNX2 signaling pathway), 
miR-29a (stimulates Wnt signaling pathway), miR-23a (inhibits RUNX2 signaling 
pathway), and miR-100 (inhibits BMPR2 signaling pathway), whereas some miRNAs 
regulate osteoclastogenesis, such as miR-21. MiR-21 and miR-125b are also involved in 
the differentiation of osteocytes from human mesenchymal stromal cells (hMSC) (84).  
In osteoporosis, miRNAs regulate the differentiation, proliferation and apoptosis 
of bone cells (84). Seeliger et al. (116) measured miRNAs in serum and bone tissues 
from patients aged over 50 yr with hip fractures compared to nonosteoporotic controls. 
They analyzed two miRNA arrays that contained miRNAs from osteoporotic patients 
and controls, respectively, and found 9 c-miRNAs (miR-21, -23a, -24, -93, -100, -122a, 
-124a, -125b, and -148a) that were significantly upregulated in osteoporotic fracture 
patients compared to controls. Additionally, 6 miRNAs (miR-21, -23a, -24, -25, -100, 
and -125b) in bone tissue were found significantly upregulated in osteoporotic fracture 
patients. Overall, 5 miRNAs were found significantly upregulated in osteoporotic 
patients in both serum and bone tissue compared to controls, including miR-21, -23a,  
-24, -100, and -125b. Panach et al. (91) measured c-miRNAs in patients with hip 
fractures and controls with severe osteoarthritis at the hip. They found 3 c-miRNAs, 
including miR-122, -125b, and -21, that were significantly upregulated in fracture 
patients compared to osteoarthritic controls. In particular, the level of miR-21 was 
correlated with the level of CTX (r=0.76, p<0.000001), a bone resorption marker.  
Aging affects miRNA expression. Drummond et al. (29) compared miRNA 
expression in skeletal muscle following acute resistance exercise and essential amino 
acids ingestion in young (mean 29 yr) and older (mean 70 yr) men. They found that 
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primary miRNAs of pri-miR-1-1 and -1-2, pri-miR-133a-1 and -133a-2 were 
significantly higher in muscle tissue in the elderly compared to young men at baseline. 
There were no differences in miRNA biogenesis pathways, including Drosha, Exportin-
5, Dicer mRNA, or mature miRNA found between young and old men at baseline. 
MiR-1 was reduced in young but not older men following exercise stimulus, indicating 
that aging results in a dysregulated miRNA response after anabolic stimulus. More 
recently, Drummond et al. (30) conducted a muscle tissue microarray study in young 
and older men and confirmed that let-7b and -7e were significantly higher in the older 
group than the young men. The let-7 family was predicted to be associated with cell 
cycle control and was validated that there was downregulation of regulators of cell 
cycle proliferation in the older group. Overall, there was lower expression of genes 
related to cell cycle regulation in skeletal muscle in older men, which may have been 
regulated by the let-7 family. This study could have been more interesting if they not 
only examined muscle tissue, but also measured serum miRNAs and compared them in 
the young and older groups.  
So far, no study has compared bone-related miRNAs in serum between younger 
and older populations. Rivas et al. (107) compared the acute miRNA responses to 
resistance exercise between younger and older men. Participants completed 3 sets of 10 
repetitions of knee extension and leg press exercises at 80% 1-RM and muscle biopsy 
was obtained 6 hours post exercise. They found that expression of 21 miRNAs were 
altered by exercise in the younger men whereas there were no changes in the older men. 
In addition, expression of 175 protein-coding genes was altered by exercise in the 
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younger men as compared to only 42 genes in the older men. MiR-126 appeared as an 
important regulator in muscle growth and IGF-1 pathways.   
MiRNAs are being recognized as important regulatory molecules in a large 
number of biological process. Studying miRNAs is a new direction in the research of 
osteoporosis and sarcopenia, and understanding miRNA expression profiles and 
dynamic regulation is able to provide new mechanisms in basic research, potential 
novel diagnostic biomarkers, and drug targets for treatment of osteoporosis and 
sarcopenia. However, numerous questions need to be addressed before utilizing 
miRNAs as a biomarker in osteoporosis and sarcopenia. 
Summary 
It is important to characterize the molecular mechanisms associated with 
osteoporosis and sarcopenia. By identifying new signaling pathways, it is likely that 
miRNAs may inspire novel approaches for the detection of osteoporosis and sarcopenia 
and provide better therapy so that more options are available for the treatment of 
osteoporosis and fracture prevention.  
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Chapter 3 Methodology 
 This cross-sectional study measured the expression levels of selected c-miRNAs 
in relation to osteoporosis and sarcopenia statuses in postmenopausal women. In 
addition, this study examined the relationships between bone-specific miRNAs and 
bone density, bone strength and bone turnover markers, and muscle-skeletal miRNAs 
and muscle mass and muscular strength. Finally, this study compared functional 
performance, muscle mass and strength, and bone density and strength among normal, 
osteopenia, and sarco-osteopenia postmenopausal women.  
Participants 
 Seventy-five community-dwelling, postmenopausal women aged between 60 to 
85 years old were recruited in this study. Fifteen of the participants were measured 
twice on bone measurements and functional performance tests. Prior to participation, 
each participant was asked to sign a written informed consent and HIPAA forms. The 
study was approved by the University of Oklahoma Health Sciences Center (OUHSC) 
Institutional Review Board (IRB#6971). Participants were recruited from Norman and 
Oklahoma City areas by mass email, flyers, newspaper advertisements, and by word of 
mouth. Participants were screened for inclusion and exclusion criteria prior to 
consenting and testing.  
Inclusion Criteria  
1. Postmenopausal women, aged 60-85 yr; 
2. Community-dwelling individuals. 
Exclusion Criteria  
1. Current smokers; 
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2. Individuals with diabetes or uncontrolled hypertension; 
3. Individuals taking medications known to affect bone metabolism, such as 
antidepressants, glucocorticoids;  
4. Body weight over 350 lbs or height over 6’4’’; 
5. Individuals with recent fractures within 12 months; 
6. Individuals with metal implants or joint replacement at hip or spine. 
Research Design 
 This cross-sectional study compared relative expression levels of bone- and 
muscle-specific c-miRNAs based on statuses of osteoporosis and sarcopenia. Three 
visits were required in this study: consenting, blood pressure, and questionnaires (visit 
one, ~1 hr), blood draw and measurement of DXA, pQCT, and familiarization (visit 
two, ~2.5 hrs), and functional performance tests (handgrip strength, gait speed, jump 
test, balance) (visit three, ~1 hr). However, to assess reliability and consistency of our 
measures, a subset of 15 participants (the first 15 participants aged 70-85 yrs who were 
willing to return for a fourth visit) repeated the measurement of DXA, pQCT, and 
functional performance in an additional visit (visit four, ~1.5 hr). The fourth visit was 3-
7 days after the third visit. The first visit was conducted at Bone Density Laboratory at 
the University of Oklahoma (OU). During the second visit, the blood draw was 
performed at OU Goddard Student Health Center, and the rest of the second, third, and 
fourth visits were conducted in the Bone Density Laboratory at OU. A medical 
clearance form signed by the participant’s physician was obtained prior to scheduling 
the second, third and fourth visits. 
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 The independent variables were status of osteoporosis (normal, osteopenia, 
osteoporosis) and sarcopenia (normal, sarcopenia). The dependent variables for blood 
analysis were relative expression levels of bone- and muscle-specific c-miRNAs (miR-
1, -21, -23a, -24, -100, -125b, -133a, -206), and levels of bone turnover markers. The 
dependent variables for the DXA were aBMD of total body, lumbar spine, and dual 
femur, and body composition. The dependent variables for the pQCT were total vBMD, 
total vBMC, and total area at tibia 4%, 38%, and 66% sites; trabecular vBMD, 
trabecular vBMC, trabecular area and BSI at tibia 4% site; cortical vBMD, cortical 
vBMC, cortical area, Ipolar, and SSI at tibia 38% and 66% sites, and muscle cross 
sectional area (CSA) at tibia 66% site. The dependent variables for functional 
performance were grip strength, gait speed, and jump power.  
Questionnaires  
 Several questionnaires were filled out by the participants to gather information 
regarding potential confounding variables that affect bone health and muscle 
performance, including menstrual history, calcium intake, and physical activity levels. 
The following questionnaires were used in this study.  
1. Health Status Questionnaire – to identify whether the participant meet the 
inclusion and exclusion criteria for the study and to record medications taken by 
the participant. 
2. Menstrual History Questionnaire – to provide information about menstrual cycle 
and hormone replacement therapy history.  
3. Bone-Specific Physical Activity Questionnaire (BPAQ) – to quantify exposure 
to bone loading physical activity throughout the lifespan (135). 
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4. Calcium Intake Questionnaire – to estimate daily calcium intake from diet and 
supplements.  
Body Weight and Height 
 Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively, 
using a wall stadiometer (PAT #290237, Novel Products, Rockton, IL) and digital 
electric scale (BWB-800, Tanita Corporation of America, Inc., Arlington Heights, IL). 
Blood Pressure 
Resting blood pressure was measured by an automatic blood pressure monitor 
(Omron, Japan) on the left arm. The participant sat in a chair with her back supported, 
legs uncrossed and feet on the floor. The measured arm was supported with the upper 
arm at heart level. The monitor was turned on with appropriated cuff size selected. The 
cuff was placed over the brachial artery and the “START” button was pressed to 
automatically increase the cuff pressure and start the measurement. The systolic and 
diastolic blood pressures, and heart rate were recorded. One minute later, the second 
measurement was performed.  If there is more than 5 mmHg difference, a third 
measurement were performed and the average of the closest two values was used. 
Hypertension was classified as systolic blood pressure above 140 mmHg or diastolic 
blood pressure above 90 mmHg. Therefore, participants with systolic blood pressure 
above 140 mmHg or diastolic blood pressure above 90 mmHg were excluded 
considering the risk when doing functional performance tests.  
Dual Energy X-ray Absorptiometry (DXA) 
Lunar Prodigy DXA (GE Healthcare, Madison, MI) was used to measure areal 
bone mineral density (aBMD) via a series of four bone scans, including the total body, 
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AP lumbar spine (L1-L4), and dual proximal femur (femoral neck, trochanter, and total 
hip). Body composition of the whole body and regional areas, such as lean mass at arms 
and legs, were also obtained through the total DXA scan. Scans were analyzed using the 
enCORE software, version 16 (GE Healthcare, Madison, WI).  
This research study involved radiation exposure from four DXA scans, which 
ranged from 0.08 to 0.18 mrem for each scan. Thus, the participants were exposed to a 
total dose of less than 6 mrem of radiation, which is similar to one transcontinental 
flight across the United States (4-6 mrem) and much less than the typical radiation 
exposure with conventional chest X-ray and CT scans (25 to 270 mrem) (57). A Quality 
Assurance (QA) test was performed to calibrate the DXA and ensure that the DXA was 
working properly at the beginning of each testing day prior to data collection. A 
standard calibration block was positioned on the DXA table, and then the software ran 
the remaining QA test automatically until completion. 
Prior to DXA scans, the participant was asked to take off shoes, wear minimal 
clothing and remove all metal, and then lie in the supine position on the table, with the 
head approximately 2-3 cm below the horizontal line at the top of the table. Hips and 
shoulders were evenly spaced in the middle of the table, with arms close to the body, 
and knees and feet secured with one strap each to keep the legs straight. Upon the 
completion of the total body scan, a foam block was placed under her legs with knees 
bent at 45-60 degrees. The participant kept hips and upper body straight, pointed out her 
navel so that the scan arm could be adjusted to 2 finger widths below the navel, and 
then held her arms upright and the lumbar spine was scanned. Once the scan was 
completed, the block was removed and the feet were placed onto each side of the foot 
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brace using the straps. The left leg was positioned straight so that the left hip was 
scanned first and then the same procedure was conducted with the right leg.  
Precision of bone density and body composition in postmenopausal women was 
assessed by the technician who measured all the participants by DXA (Table 1). The 
root mean square (RMS) coefficient of variation (CV%) was calculated using the 
International Society for the Clinical Densitometry (ISCD) Bone Densitometry 
Precision Calculating Tool. The CV% for lumbar spine, femoral neck, and total hip 
were within the minimum acceptable precision according to the 2015 ISCD Adult 
Official Position Stands (118).  
Table 1. Precision for Bone Density and Body Composition Measurements by DXA 
Variable CV% 
Total Body aBMD 1.27% 
Lumbar Spine L1-L4 aBMD 1.80% 
Left Femoral Neck aBMD 1.79% 
Right Femoral Neck aBMD 1.33% 
Left Total Hip aBMD 1.19% 
Right Total Hip aBMD 1.00% 
BFLBM 1.21% 
Fat Mass 1.74% 
Body Fat% 1.56% 
Arms BFLBM 3.97% 
Legs BFLBM 2.29% 
ASM 2.08% 
ASM: Appendicular Skeletal Muscle Mass 
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Peripheral Quantitative Computed Tomography (pQCT) 
Peripheral Quantitative Computed Tomography (pQCT) is an effective 
supplement to DXA providing detailed information about the cross-sectional geometry 
of skeletal sites. It measures the true volumetric values of BMD and discriminates 
between the trabecular and cortical components of bone. Also, pQCT scans assess bone 
stress strain index (SSI) at multiple sites, thus providing additional information about 
bone density, bone composition, and bone strength.  
A XCT-3000 bone scanner (Stratec Medizintechnik GmbH, Pforzheim, 
Germany) was used for the epiphyseal and diaphyseal bone measurements of the non-
dominant tibia and bone images were analyzed using the integrated software version 
6.00 in this study (Stratec Medizintechnik GmbH, Pforzheim, Germany). Scans were 
obtained with a voxel size of 0.4 mm, a slice thickness of 2.2 mm, and a scan speed of 
20 mm/sec. The 4% tibia total and trabecular bone analyses were performed with the 
following parameters: Contmode 3, Peelmode 4, trabecular thresholds of 169 mg/cm3 
and 650 mg/cm3. Contmode 3 used automated contour detection with a user-defined 
threshold. Peelmode 4 was a threshold driven peel that also utilized a filter. After the 
initial peel to define cortical and trabecular bone was completed, Peelmode 4 then 
peeled a set percentage (10%) of the total bone area from the endosteal edge found by 
the initial peel. This method separated trabecular bone from the cortical + subcortical 
bone, so as to prevent higher density voxels from being included in the trabecular 
analysis. The total bone analysis at the 38% and 66% site was performed using 
threshold driven modes Contour Mode 1 and Peel Mode 2 with a threshold of 710 
mg/cm3. The cortical bone analysis was performed using Cortical Mode 2, a threshold 
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driven separation mode with a filter, with a threshold of 710 mg/cm3. When 
determining SSI, a threshold of 480 mg/cm3 was used. Muscle CSA analysis was 
performed as a combination of two analyses. The first trabecular parameter was 
Contour Mode 3 with Peel Mode 2, using thresholds of -100 mg/cm3 and 40 mg/cm3. 
The second trabecular parameter was Contour Mode 1 and Peel Mode 2, using 
thresholds of 710 mg/cm3 and 40 mg/cm3. Cortical parameters were only utilized for the 
first analysis, using a threshold of 710 mg/cm3 in Contour Mode 1. Smoothing filter 
F03F05 was used. Muscle CSA at the tibia 66% site was defined with the following 
equation: Subcortical area (Analysis 1) – Cortical Area (Analysis 1). The cone phantom 
calibration was performed at the beginning of each testing day prior to the participant 
being scanned, and the cortical calibration was performed every 7 days.  
Non-dominant tibia length was measured by a tape measure in “mm” prior to 
scanning. When measuring the tibia, the participant sat on a chair and crossed her non-
dominant leg over the other knee. The length of the tibia was measured from the end of 
the medial malleolus at the ankle to the endplate of the tibia plateau at the proximal 
tibia. A small pen mark was made at these bony landmarks when making 
measurements.  
After entering the participant’s basic information in the computer, the 
participant sat on the chair of the pQCT and put the non-dominant leg on the leg and 
foot support. The chair position was adjusted to make sure the individual’s leg was 
centered and straight while seated. Straps were put around the foot and knee to stabilize 
the leg. Then the laser point in the gantry was positioned directly below the pen marker 
on the ankle, and the Scout View (SV) was obtained first to find the start position for 
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the tibia scanning. Based on the SV, the reference line was placed at the middle of the 
“football area” (tibio-talar joint), and the cross-sectional CT scan started obtaining the 
bone images. Similarly, the SV was assessed first at the distal lateral endplate of the 
femur to locate the start position for the femur scanning and then started the cross-
sectional CT scans at the 50% of the femur length from distal. The participant was 
required to remain still throughout the whole scanning. All pQCT scans were performed 
by the same qualified technician. 
All participants had their total and trabecular vBMD at tibia 4% site, total and 
cortical vBMD at tibia 38% and 66% sites, and muscle CSA at tibia 66% sites measured 
by pQCT. Participants received radiation exposure of an absorbed dose of 1 mrem from 
each scan, which was almost the amount of radiation exposure that Americans receive 
in one day from natural background radiation (300mrem/year) from sources such as 
radioactivity in the soil.   
Precision of volumetric bone variables was assessed by the technician who 
measured all the participants on PQCT. Similarly, the coefficient of variation (CV%) 
was calculated using the ISCD Bone Densitometry Precision Calculating Tool, and the 
results are shown in Table 2. Overall, the precision for measuring volumetric bone 
variables in postmenopausal women ranged from 0.29% to 3.07% depending on the site 





Table 2. Precision for Volumetric Bone Measurements by PQCT 
Site Variable CV% 
4% Total vBMD  1.12% 
Total vBMC  2.00% 
Trabecular vBMD  0.68% 
Trabecular vBMC  3.07% 
Peri_C  1.23% 
38% Total vBMD  0.29% 
Total vBMC  0.48% 
Cortical vBMD  0.29% 
Cortical vBMC  0.61% 
SSI  1.29% 
Iploar  0.84% 
66% Total vBMD  1.51% 
Total vBMC  0.92% 
Cortical vBMD  0.50% 
Cortical vBMC  1.85% 
Peri_C  0.49% 
Endo_C  1.45% 
SSI  1.49% 
Iploar  1.08% 
Muscle CSA 1.73% 
Peri_C: Periosteal Circumference; Endo_C: Endosteal Circumference; SSI: Stress 
Strain Index; Muscle CSA: Muscle Cross-sectional Area 
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Muscle Functional Performance Measurements 
Handgrip Test 
Grip strength was measured using a handgrip dynamometer (Takei Scientific 
Instruments, Yashiroda, Japan) while in seated position. The participant flexed her 
elbow at 90 degrees with the forearm in a neutral position and the wrist between 0-30 
degrees dorsiflexion, and 0-15 degrees ulnar deviation in the dominant hands. The 
Takei dynamometer was used first. The grip width was adjusted so that the instrument 
felt comfortable to squeeze in the hand. Once in position, starting from the right hand, 
the participant was encouraged to squeeze as hard as possible or until the needle 
stopped rising for about 3-5 seconds. The same measurement was repeated in the left 
hand and two further measurements for each hand alternating sides to give 3 readings in 
each side. The results were recorded to the nearest 0.1 kg and the maximal handgrip 
strength was used in analyses. 
Gait Speed Test 
Gait speed was measured using an 8-meter straight path marked with tape. Any 
usual walking aids, such as cane or walker, were allowed in the test. After the tester’s 
command of “Go”, the participant started to walk at their usual pace along the path. 
Digital stopwatch was used to record the time. Three repetitions were performed and a 
minimum of 1 min rest between trials or as long as the participant needed was given. 
Trained testers supervised the testing process. The average time of three repetitions was 
used to calculate the gait speed (distance/time).  
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Jump Test 
Muscle power was assessed by a jump test on a jump mat (Just Jump, Probotic, 
AL) with a Tendo FiTRODYNE power and speed analyzer (Tendo Sports Machines, 
Trencin, Slovak Republic). Farias et al. (36) reported that the contact mat provided a 
reliable vertical jump power in older women (ICC=0.91). Rogan et al. (110) found 
strong correlations between jump mat and force plate results in terms of jump height 
(r=0.99) and ground contact time (r=0.98) in young adults. The participant in our study 
was asked to do a countermovement vertical jump by crouching, then jumping with 
non-restricted arm motion, and then landing on the jump mat. Trained spotters were 
standing on either side of the participant to help with balance, if needed. A transfer belt 
was fastened around the waist of the participant and was held by the spotter to stabilize 
the participant if she lost her balance. A minimum of 1 min or as long as the participant 
needed was allowed between jumps, and 3 successful jumps were performed by each 
participant. The average performance of the three trials was used in the data analysis.  
The test-retest reliability of functional performance tests (grip strength, gait 
speed, and jump test) in postmenopausal women was assessed by the technician who 
tested all the participants. The values are shown in Table 3. The intraclass correlation 
(ICC) ranged from 0.78 to 0.94 and the Pearson r ranged from 0.81 to 0.94. Overall, 





Table 3. Test-retest Reliability of Functional Performance Measurements 
Variable Day 1 Day 2 ICC (3,1) Pearson r 
Grip Strength (kg) 22.6 ± 4.2 22.7 ± 4.9 0.874 0.885 
Gait Speed (m/s) 1.22 ± 0.15 1.24 ± 0.15 0.821 0.821 
JHt (inch) 5.9 ± 1.7 5.8 ± 1.7 0.942 0.942 
JVel (m/s) 0.85 ± 0.16 0.88 ± 0.13 0.784 0.805 
JP (W) 613.3 ± 141.3 638.2 ± 131.9 0.839 0.841 
JHt: Jump Height; JVel: Jump Velocity; JP: Jump Power; Day 1 and Day 2 were 
reported as Mean ± SD; ICC: Intraclass Correlation  
 
Sarcopenia Classification 
Sarcopenia status in postmenopausal women was determined based on the 
conventional definition as well as the criteria set by EWGSOP (23). Conventional 
definition: skeletal muscle mass index (SMI) < -2 SD average reference population, that 
is, SMI < 5.5 kg/m2 for women. EWGSOP criteria for women: gait speed < 0.8 m/s or 
grip strength < 20 kg, plus SMI < 5.5 kg/m2. 
Blood Sampling  
 A blood sample of 7.5 ml was collected via venipuncture by a registered nurse 
or phlebotomist at the OU Goddard Student Health Center in the early morning between 
8:00 a.m. and 9:00 a.m. after an 8-hour overnight fasting to measure levels of c-
miRNAs and BTMs. After the blood sample was drawn, it was allowed to clot for at 
least 30 min and then centrifuged at 2,000 g for 15 min. Following that, serum samples 
were transported to the PI’s laboratory, aliquoted into 10 microtubes, and immediately 
frozen at -84 °C until analyzed.  
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Biochemical Markers of Bone Turnover 
 Prior to the assay, frozen samples along with all reagents were thawed at room 
temperature. Levels of bone resorption markers, CTX and TRAP5b, and bone formation 
marker, P1NP were measured in duplicate using the ELISA kits. The CTX 
(Immunodiagnostic Systems, Gaithersburg, MD) and TRAP5b (Quidel, Athens, OH) 
assays were performed following step by step kit instructions (Appendices E & F). The 
intra-assay CV% were 1.3-15.2%, and the inter-assay CV% were 1.3-7.0%. So far, most 
of the P1NP assays are performed using automated immunoassay systems, which was 
not available in our laboratory. We tried two manual immunoassay kits from two 
companies (US Biological, Salem, MA and Cloud-Clone, Wuhan, China), but the P1NP 
results were inconsistent thus were not used in data analysis.  
Selection of Candidate MiRNAs 
 Three muscle-specific miRNAs and five bone-specific miRNAs (miR-1-3p, -21-
5p, -23a-3p, -24-3p, -100-5p, -125b-5p, -133a-3p), were selected as representatives of 
those previously implicated underlying cellular processes (Table 4). For simplicity, they 
are referred to as miR-1, -21, -23a, -24, -100, -125b, -133a throughout the chapters. 
Note that some of these miRNAs regulate several functions. For example, miR-21 has 
been reported to be associated with both osteoporosis and fractures (116) and 
sarcopenia in the elderly (17). MiR-133a not only regulates myogenesis, but it is also a 




Table 4. Candidate miRNAs that Regulate Cellular Processes in Muscle and Bone 
MiRNA Target(s) Biological Function 
miR-1 PAX7, IGF1, etc. + myoblast differentiation 
miR-133a RUNX2 - osteoblast differentiation 
SLC39A1, etc. + myoblast differentiation 
miR-206 CX43 - osteoblast differentiation 
PAX7, etc. + myoblast differentiation 
miR-21 PDCD4, FASL + osteoblast differentiation and mineralization; 
+ osteoclastogenesis and bone-resorbing activity  
EIF4E3, PDCD4 - apoptosis of muscle fiber (123) 
miR-23a RUNX2 - osteoblast differentiation 
miR-24 RUNX2 - osteoblast differentiation 
miR-100 BMPR2 - osteoblast differentiation  
miR-125b PDGF + osteocytes and chondrocytes differentiation; 
- osteoblast differentiation 
+: promote; -: inhibit 
RNA Extraction  
 Total RNA was extracted using the miRNeasy Serum/Plasma Kit (Qiagen, 
Hilden, Germany) following the step by step procedures in the kit instructions 
(Appendix G). Serum samples were thawed at room temperature. 200 µL of serum was 
used for sample lysis by mixing with 1000 µL QIAzol Lysis Reagent. RNA extraction 
was performed using 200 µL chloroform and phase separation was achieved by 
centrifugation for 15 min at 12,000 g at 4°C. 650-750 µL of the upper aqueous phase 
was transferred to a new collection tube, which was further precipitated and purified on 
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the QIAcube (Qiagen, Hilden, Germany). Spin columns were washed with RWT buffer, 
RPE buffer and 80% ethanol. In the last step, RNA was eluted in 15 µL RNase-free 
water, which yielded 13 µL of total RNA. RNA purity was determined using a DeNovix 
DS-11 Spectrophotometer (DeNovix, Wilmington, DE): Selected the RNA app, first 
established a Blank using 1 µL of RNase-free water, then measured the RNA 
concentration using 1 µL of extracted RNA. The full spectrum analysis was generated, 
providing the absorbance values at 260 nm (A260) and the ratio of the 260 nm and 280 
nm (A260/A280). To ensure significance, A260 readings should be greater than 0.15. 
A260/A280 gives an estimate of RNA purity, with readings of 1.9-2.1 indicating pure 
RNA. RNA concentration results were reported in ng/µL. Extracted RNA samples were 
immediately frozen in a -80°C freezer. Two-step quantitative reverse-transcription PCR 
(qRT-PCR) was used for RNA quantification: first of all, cDNA synthesis (reverse 
transcription), and then about 10% of cDNA is transferred for real-time PCR. 
cDNA Synthesis 
The extracted total RNA was transcribed to cDNA using the TaqMan Advanced 
miRNA cDNA Synthesis Kit (Applied Biosystems, Foster City, CA) via a TC-412 
Thermal Cycler (Techne, UK). Starting with a total RNA sample, poly(A) polymerase 
was used to add a 3’-adenosine tail to the miRNA. Then the miRNA with poly(A) tail 
underwent adaptor ligation at the 5’ end. The adaptor acts as the forward-primer binding 
site for the miR-Amp reaction. Therefore, all miRNAs were amplified in a single 
reverse transcription (RT) reaction. Then a universal RT primer bound to the 3’ poly(A) 
tail and the miRNA was reverse transcribed. During miR-Amp reaction, universal 
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forward and reverse primers increase the number of cDNA molecules. The kit 
instructions are listed in Appendix H (Section 2).  
Total RNA and cDNA synthesis reagents were thawed to room temperature on 
ice. 2 µL of total RNA were mixed with 3 µL Poly(A) Reaction Mix in PCR 8-tube 
strips to perform polyadenylation in thermal cycler for 55 min. Then 10 µL of the 
Ligation Reaction Mix was added to each tube containing the poly(A) tailing reaction 
product, and legation was performed in thermal cycler for 60 min. Following that, 15 
µL of the Reverse Transcription Reaction Mix was added to each tube containing the 
adaptor ligation reaction product, and Reverse Transcription (RT) was performed in the 
thermal cycler for 20 min. Finally, 45 µL of the miR-Amp Reaction Mix and 5 µL of 
the RT reaction were mixed in each new PCR tube, and universal cDNA reaction was 
performed in a T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA) to amplify 
the cDNA molecules through the following steps: enzyme activation, denaturing and 
annealing cycles, and stop reaction. Eventually, a total volume of 50 µL miR-Amp 
reaction product of each sample was frozen in -80°C freezer immediately.  
Quantification of MiRNA Expression 
 TaqMan Advanced miRNA assays (Applied Biosystems, Foster City, CA) and 
quantitive real-time Polymerase Chain Reaction (qPCR) were used to quantify the 
relative expression levels of selected c-miRNAs. TaqMan-based detection uses a 
fluorogenic probe specific to a target gene to detect the target. The TaqMan MGB 
probes contain a reporter dye at the 5’ end of the probe and a non-fluorescent quencher 
(NFQ) dye at the 3’ end of the probe. The NFQ dye does not fluoresce, which allows 
the real-time PCR to measure the reporter dye contributions more accurately. During 
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the PCR, the forward and reverse primers anneal to the complementary sequences along 
the denatured cDNA template strands. The TaqMan MGB probe anneals specifically to 
a complementary sequence between the forward and reverse primer sites. During 
polymerization, the DNA polymerase only cleaves probes that hybridize to the target 
sequence. Cleavage separates the reporter dye from the probe, which results in 
increased fluorescence by the reporter dye. The kit instructions are provided in 
Appendix H (Section 3). 
Each 10 µL miR-Amp reaction was diluted with 180 µL 0.1X TE buffer (1:10) 
to prepare 200 µL of diluted cDNA template, and then 100 µL of each was aliquoted 
into PCR 8-tube strips and kept in -20°C freezer. 15 µL of PCR Reaction Mix was 
mixed with 5 µL of the diluted cDNA template in triplicate in a Fast Optical 96-well 
PCR Reaction Plate with Barcode (Applied Biosystems, Foster City, CA). Three wells 
of internal control (positive control) and another 3 wells of non-template control 
(negative control) were included at the end of each PCR reaction plate. Then the PCR 
reaction plate was sealed with MicroAmp Optical Adhesive Film (Applied Biosystems, 
Foster City, CA) and the contents briefly spun down using MPS 1000 Mini PCR Plate 
Spinner (Labnet International, Woodbridge, NJ) to eliminate air at the bottom of wells. 
Then the PCR reaction plate was loaded in the 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA), and cDNA was amplified via fluorescently 
labeled Taqman probes and primers with the following settings: 50°C for 2 min, 95°C 
for 2 min (Enzyme activation), 45 cycles of 95°C for 1 s (Denaturation) and 60°C for 20 
s (Annealing/Extension).  
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miR-16-5p, -93-5p, and -191-5p were selected as endogenous controls based on 
previous literature. The RQ Manager, version 1.2.1 (Applied Biosystems, Foster City, 
CA) was used to detect the Ct values to further analyze the real-time PCR results. The 
relative expression levels of target miRNAs were normalized to the normalization 
factor, which was calculated as the geometric mean of the three endogenous controls 
(miR-16-5p, -93-5p, -191-5p). Furthermore, fold changes were calculated using the 2 -
∆∆Ct method (19). MiRNAs with Ct ≥ 37 were considered not expressed. 
Data Analyses 
 Statistical analyses were performed using IBM SPSS Statistics (SPSS Inc., 
Chicago, IL), version 22. The relative expression levels of c-miRNA are reported as 
mean ± standard error (SE), and the rest of descriptive data are reported as mean ± 
standard deviation (SD). Normality of the dependent variables was assessed using the 
Shapiro-Wilk tests. Variables of physical characteristics, bone and muscle, and 
functional performance were normally distributed (p > 0.05). However, variables of 
miRNAs and BPAQ scores were not normally distributed (p <0.05). Osteoporosis was 
determined using aBMD T-scores at lumbar spine, femoral neck, or total hip according 
to WHO criteria (aBMD T-score ≤ -2.5), whereas sarcopenia was determined using 
conventional, as well as EWGSOP (23), definitions. Participants were further divided 
into normal (aBMD T-score > -1 with normal SMI), osteopenia (aBMD T-score ≤ -1 
with normal SMI), sarcopenia (aBMD T-score > -1, SMI ≤ 5.5 kg/m2) and sarco-
osteopenia (aBMD T-score ≤ -1, SMI ≤ 5.5 kg/m2) groups. However, there only one 
participant fell into the sarcopenia group, which was excluded from ANOVA analysis. 
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Chi-square analyses were used to examine the associations between the prevalence of 
osteoporosis and sarcopenia. 
Independent samples t-test was used to compare physical characteristics, bone 
and muscle variables, functional performance between two groups 
(normal/osteoporosis, normal/sarcopenia), whereas one-way ANOVA was used to 
compare them among normal, osteopenia, and sarco-osteopenia groups. In order to 
minimize inflation of the Type I error, a Bonferroni correction was made to adjust the 
level of significance (p ≤0.05/number of tests). Relative expression levels of target c-
miRNAs (miR-1, -21, -23a, -24, -100, -125b, -133a, -206) in osteoporosis group alone, 
sarcopenia group alone, or osteopenia and sarco-osteopenia groups were compared to 
that of the normal group. Two-tailed Mann-Whitney U tests were used to compare the 
relative expression levels of c-miRNAs between normal and osteoporosis groups, and 
normal and sarcopenia groups, whereas two-tailed Kruskal-Wallis tests were used to 
compare the relative expression levels of c-miRNAs among normal, osteopenia, and 
sarco-osteopenia groups. Spearman correlation analysis was used to test the 
relationships between the c-miRNAs and age, bone variables, muscle mass, muscular 
strength, and muscle power. The level of significance was set at p ≤ 0.05.  
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Chapter 4 Results and Discussion 
The purpose of this study was to identify specific c-miRNAs that are associated 
with bone and muscle status in postmenopausal women, and to evaluate the use of these 
c-miRNAs as biomarkers of osteoporosis and sarcopenia. In addition, this study 
examined the associations between specific c-miRNAs and bone turnover markers as 
well as sarcopenia parameters. 
Participant Characteristics 
 A total of 123 postmenopausal women aged 60 to 85 years old were screened for 
this study. Ninety-nine participants met the pre-screening criteria and signed the consent 
form. Of the 99 participants, 24 participants were excluded from the study for the 
following reasons: 6 due to time conflicts, 12 having hypertension, 2 taking 
antidepressants drug SSRI (Selective Serotonin Reuptake Inhibitors), another 2 taking 
thiazide medication, 1 due to recent fractures within 12 months, and another 1 because 
the phlebotomist was not able to get blood draw from her. Therefore, a total of 75 
postmenopausal women aged 60 to 85 years old met all the inclusion criteria and 
completed the study in the Bone Density Laboratory. Among these 75 participants, only 
one participant was Asian and the rest of them were Caucasian. 31 participants had 
taken HRT (hormone replacement therapy) in the past, 19 participants were currently 
taking HRT (7 months to 45 years), and 5 participants were on bisphosphonate 
treatment, including 3 participants taking both HRT and bisphosphonate treatment.   
 The number of participants and the prevalence of osteoporosis and sarcopenia 
among the participants are displayed in Table 5. The prevalence of sarcopenia based on 
the conventional definition was about three times of that based on the EWGSOP 
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definition. Osteopenia and osteoporosis were particularly common in this group of 
participants with a total percentage of 81% (n=61). Because the sarcopenia sample size 
was much smaller based on the EWGSOP definition, sarcopenia based on the 
conventional definition was used for statistical analyses in this study. Chi-square 
analysis showed that there was no significant association between sarcopenia and 
osteopenia statuses in this group of participants (Table 6). Also, there was no significant 
association between bone status and current HRT status (Table 7). However, there was 
a trend for significant positive association (p = 0.056) between muscle status and 
current HRT status (Table 8), which indicates that HRT current users have a potentially 
higher prevalence of sarcopenia than HRT non-users.  
Table 5. Classification of Participants based on Bone and Muscle Status 
Criteria Classification Number Percent 
aBMD Status Normal 14 18.7% 
Osteopenia 51 68.0% 
Osteoporosis 10 13.3% 
Sarcopenia Status  
(Conventional) 
Normal 59 78.7% 
Sarcopenia 16 21.3% 
Sarcopenia Status  
(EWGSOP) 
Normal 69 92.0% 






Table 6. Association between the Bone and Muscle Status 
Classification Sarcopenia (n=16) Non-sarcopenia (n=59) P 
Normal aBMD (n=14) 7.1% (1) 92.9% (13) 
0.153 Osteopenia (n=51) 21.6% (11) 78.4% (40) 
Osteoporosis (n=10) 40.0% (4) 60.0% (6) 
 
Table 7. Association between Bone and Current HRT Status 
Classification HRT Users (n=19) Non-Users (n=56) P 
Normal aBMD (n=14) 35.7% (5) 64.3% (9) 
0.360 Osteopenia (n=51) 25.5% (13) 74.5% (38) 
Osteoporosis (n=10) 10.0% (1)  90.0% (9) 
HRT Users: Participants currently taking hormone replacement therapy (HRT) over 6 
months 
 
Table 8. Association Between Muscle and Current HRT Status 
Classification HRT Users (n=19) Non-Users (n=56) P 
Normal (n=59) 20.3% (12) 79.7% (47) 
0.056 
Sarcopenia (n=16) 43.8% (7) 56.3% (9) 
HRT Users: Participants currently taking hormone replacement therapy (HRT) over 6 
months 
 
Altogether, 17.3% of participants (NOR, n=13) had normal muscle mass and 
aBMD, 61.3% of participants (OP, n=46) had osteopenia with normal muscle mass, 
20% of participants (SOP, n=15) had both sarcopenia and osteopenia (sarco-
osteopenia), whereas only one participant (SP, n=1, 1.3%) who had been on hormone 
replacement therapy (HRT) for over 45 years had sarcopenia with normal aBMD. 
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Therefore, the statistical analysis of comparisons was performed only in the other three 
groups (NOR, OP, and SOP). 
The characteristics of normal, sarcopenia, osteopenia, and sarco-osteopenia 
groups are provided in Table 9. One to seven participants of each group were currently 
taking HRT for at least 6 months. There were no significant differences in age, height, 
calcium intake, BPAQ scores, or self-reported HRT history in normal, osteopenia, and 
sarco-osteopenia groups. However, the sarco-osteopenia group had significantly lower 
body weight than the normal (p = 0.005) and osteopenia (p = 0.001) groups.  
Table 9. Physical Characteristics of the Participants 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Age (yr) 68.9 ± 6.5 69.6 ± 5.6 68.9 ± 5.2 85.8 
Height (cm) 165.3 ± 5.9 162.0 ± 6.3 163.4 ± 6.1 161.5 
Weight (kg) 71.5 ± 11.9 70.0 ± 11.6 58.1 ± 6.6**†† 61.2 
Ca2+ (mg/day) 1730.8 ± 800.9 1486.8 ± 677.8 1630.6 ± 669.3 487.9 
BPAQ Past 72.5 ± 58.0 81.7 ± 62.4 130.0 ± 140.9 4.8 
BPAQ Current 4.9 ± 6.2 3.6 ± 5.0 4.8 ± 6.0 0.3 
BPAQ Total 38.7 ± 29.2 42.6 ± 31.9 67.4 ± 71.1 2.5 
HRT Users (n/%) 5/38.5% 7/15.2%  6/40% 1/100% 
HRT Time (yr) 19.0 ± 15.0 13.4 ± 10.4 17.3 ± 7.4 45 
Mean ± SD; Ca++: Calcium Intake; HRT Users (n/%): Number and percentage of 
participants in each group that were current taking HRT; HRT Time: self-reported 
duration of current use of HRT; ** p < 0.01 significant difference between NOR and 
SOP groups; †† p < 0.01 significant difference between OP and SOP groups 
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Table 10 displays body composition for the four groups of participants. The 
sarco-osteopenia group had significantly lower muscle mass (p < 0.001) for the total 
body, arms, and legs, and fat mass for the arms (p = 0.025 and p = 0.007, respectively) 
than the normal and osteopenia groups. In addition, fat mass at the total body (p = 
0.031) and leg sites (p = 0.044) were significantly lower in the sarco-osteopenia group 
compared to the osteopenia group. Overall, the sarco-osteopenia group had significantly 
lower (approximately 20%) appendicular bone free lean mass than the normal and 
osteopenia groups (p < 0.001). 
Table 10. Body Composition of the Participants 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
% Body Fat 39.8 ± 6.7 40.8 ± 7.0 37.7 ± 5.4 42.0 
BFLBM (kg) 39.6 ± 3.6 38.7 ± 4.0 33.4 ± 2.0***††† 33.7 
FM (kg) 28.8 ± 9.1 28.7 ± 9.3 21.9 ± 5.3† 26.0 
Arm %Fat 37.9 ± 7.5 37.6 ± 8.0 33.9 ± 5.8 47.8 
Arm BFLBM (kg) 3.9 ± 0.4 3.8 ± 0.5 3.2 ± 0.4***††† 3.2 
Arm FM (kg) 2.7 ± 0.9 2.6 ± 0.9 1.8 ± 0.5*†† 3.1 
Leg %Fat 42.8 ± 7.0 43.4 ± 7.7 41.6 ± 6.0 37.8 
Leg BFLBM (kg) 12.9 ± 1.2 12.8 ± 1.7 10.5 ± 1.0***††† 10.3 
Leg FM (kg) 10.8 ± 3.8 11.0 ± 3.9 8.3 ± 2.3† 6.7 
ASM (kg)  16.8 ± 1.5 16.7 ± 2.1 13.7 ± 1.3***††† 13.5 
Mean ± SD; BFLBM: Bone Free Lean Body Mass; FM: Fat Mass; ASM: Appendicular 
Skeletal Muscle Mass; * p < 0.05; *** p < 0.001 significant difference between NOR and 
SOP groups; † p < 0.05; †† p < 0.01; ††† p < 0.001 significant difference between OP and 
SOP groups 
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Physical Functional Performance 
Table 11 shows the functional performance for the four groups of participants. 
Compared to the normal group, the sarco-osteopenia group had significantly lower grip 
strength (p = 0.008). In addition, the sarco-osteopenia group had significantly lower 
(approximate 20%) jump power than the normal and osteopenia groups (p = 0.044 and p 
= 0.003, respectively). However, there were no significant differences in gait speed, 
jump height, jump velocity, or relative jump power among the normal, osteopenia, and 
sarco-osteopenia groups.  
Table 11. Functional Performance of the Participants 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Grip Strength (kg) 26.7 ± 4.6 24.5 ± 3.9 21.8 ± 4.9** 13.1 
Gait Speed (m/s) 1.28 ± 0.17 1.30 ± 0.19 1.31 ± 0.18 1.24 
JHt (inch) 7.6 ± 1.8 7.2 ± 2.2 7.9 ± 2.0 5.73 
JVel (m/s) 0.86 ± 0.17 0.89 ± 0.15 0.85 ± 0.12 0.81 
JP (W) 600 ± 132.0 608.2 ± 125.5 485.0 ± 95.3*†† 497.67 
Relative JP (W/kg) 8.46 ± 1.72 8.76 ± 1.47 8.32 ± 1.18 8.13 
Mean ± SD; JHt: Jump Height; JVel: Jump Velocity; JP: Jump Power; * p < 0.05; ** p < 
0.01 significant difference between NOR and SOP groups; †† p < 0.01 significant 
difference between OP and SOP groups 
 
Areal Bone Mineral Density (aBMD) 
 Table 12 shows the areal bone mineral density (aBMD) for the total body, 
lumbar spine, and dual femur sites in the four groups of participants. Overall, the 
osteopenia and sarco-osteopenia groups had significantly lower aBMD than the normal 
group (p < 0.01). 
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Table 12. Areal Bone Mineral Density Measured by DXA 
Variable 
Group 
Normal (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Total Body 1.199 ± 0.057 1.110 ± 0.097## 1.089 ± 0.104** 1.203 
Lumbar Spine 1.264 ± 0.154 1.073 ± 0.163## 1.044 ± 0.140** 1.339 
Left FN 0.976 ± 0.065 0.835 ± 0.083### 0.796 ± 0.098*** 0.948 
Right FN 0.969 ± 0.064 0.836 ± 0.074### 0.804 ± 0.088*** 0.923 
Left Troch 0.814 ± 0.068 0.717 ± 0.095## 0.652 ± 0.109*** 0.801 
Right Troch 0.799 ± 0.065 0.707 ± 0.088## 0.660 ± 0.115*** 0.784 
Left Tot Hip 1.008 ± 0.058 0.881 ± 0.091### 0.828 ± 0.104*** 0.992 
Right Tot Hip 0.990 ± 0.060 0.872 ± 0.087### 0.832 ± 0.103*** 0.970 
Mean ± SD; ## p < 0.01; ### p < 0.001 significant difference between NOR and OP 
groups; ** p < 0.01; *** p < 0.001 significant difference between normal and SOP groups 
 
Volumetric Bone Variables 
 Tables 13, 14 and 15 illustrate the volumetric bone density, bone mass, and bone 
strength at 4%, 38% and 66% of the tibia, respectively. No significant differences in 
these bone variables were observed between groups, except for cortical vBMC which 
was significantly lower at 38% of the tibia in the sarco-osteopenia group than the 
normal group (p = 0.042). Furthermore, the sarco-osteopenia group had significantly 
smaller (approximately 10%) muscle CSA at 66% of the tibia than the normal and 
osteopenia groups (p = 0.001 and p < 0.001, respectively). When participants were 
classified by bone status alone, the osteoporotic group had significantly lower vBMD, 
vBMC, and BSI at 4% of the tibia than the normal and osteopenia groups (p < 0.01). At 
the 38% and 66% of the tibia, the osteoporotic group had significantly lower total and 
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cortical vBMC, cortical area, and SSI than the normal and osteopenia groups (p < 0.05), 
and significantly lower total vBMD than the normal group (p < 0.05).  
Table 13. Volumetric Bone Variables at Tibia 4% Site 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Tot vBMD  (mg/cm3) 288.5 ± 43.7 264.6 ± 33.9 261.8 ± 36.2 319.1 
Tot vBMC (mg/mm) 277.2 ± 31.7 262.0 ± 35.9 254.4 ± 43.6 274.3 
Tot Area (mm2) 969.7 ± 82.8 995.9 ± 117.4 973.0 ± 113.7 859.5 
Trab vBMD (mg/cm3) 243.1 ± 38.7 226.8 ± 32.1 232.1 ± 36.8 281.0 
Trab vBMC (mg/mm) 191.7 ± 22.7 185.6 ± 30.0 187.8 ± 37.2 197.5 
Trab Area (mm2) 797.1 ± 77.9 822.8 ± 103.9 809.7 ± 100.6 702.9 
Peri_C (mm) 110.3 ± 4.5 111.7 ± 6.7 110.4 ± 6.4 103.9 
Total BSI (mg2/mm4)  81.2 ± 19.9 70.1 ± 16.0 67.7 ± 18.9 87.5 
Trab BSI (mg2/mm4) 47.3 ± 12.6 42.7 ± 11.3 44.6 ± 14.2 55.5 











Table 14. Volumetric Bone Variables at Tibia 38% Site 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Tot vBMD (mg/cm3) 911.1 ± 66.5 856.9 ± 75.5 857.0 ± 91.2 970.7 
Tot vBMC (mg/mm) 311.6 ± 22.4 297.8 ± 34.0 281.2 ± 34.9 306.0 
Tot Area (mm2) 343.7 ± 34.3 348.8 ± 39.5 328.8 ± 29.6 315.2 
Cort vBMD (g/cm3) 1175.4 ± 24.9 1153.6 ± 34.9 1166.0 ± 33.9 1200.3 
Cort vBMC (mg/mm) 296.9 ± 23.6 282.2 ± 35.2 264.5 ± 37.4* 295.6 
Cort Area (mm2) 252.6 ± 19.5 244.7 ± 31.0 226.6 ± 29.3 246.2 
Peri_C (mm) 65.6 ± 3.3 66.1 ± 3.7 64.2 ± 2.9 62.9 
Endo_C (mm) 33.5 ± 4.9 35.8 ± 5.0 35.6 ± 4.5 29.4 
Ipolar (mm4) 19608 ± 3397 19531 ± 4152 17143 ± 2937 16909 
SSI (mm3) 1409.0 ± 184.8 1387.8 ± 223.8 1277.5 ± 168.5 1249 
Mean ± SD; Tot: Total; Cort: Cortical; Peri_C: Periosteal Circumference; Endo_C: 
Endosteal Circumference; SSI: Stress Strain Index; * p < 0.05 significant difference 










Table 15. Volumetric Bone Variables at Tibia 66% Site 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
Tot vBMD (mg/cm3) 670.5 ± 67.6 611.1 ± 86.8 636.0 ± 91.5 744.3 
Tot vBMC (mg/mm) 337.2 ± 29.1 316.0 ± 40.6 305.0 ± 45.7 339.7 
Tot area (mm2) 506.5 ± 54.3 523.0 ± 69.6 481.3 ± 46.0 456.5 
Cort vBMD (g/cm3) 1122.7 ± 23.8 1098.9 ± 36.5 1116.9 ± 32.1 1156.5 
Cort vBMC (mg/mm) 302.0 ± 28.9 275.3 ± 43.2 267.3 ± 49.9 314.7 
Cort area (mm2) 268.9 ± 24.6 250.1 ± 36.4 238.8 ± 40.8 272.2 
Peri_C (mm) 79.7 ± 4.2 80.9 ± 5.4 77.7 ± 3.7 75.7 
Endo_C (mm) 54.3 ± 5.8 58.1 ± 7.5 54.9 ± 5.8 48.1 
Ipolar (mm4) 36205 ± 6080 35505 ± 7591 30709 ± 5604 31569 
SSI (mm3) 2067.8 ± 225.0 2023.1 ± 332.1 1856.3 ± 296.4 1916.4 
Muscle CSA (mm2) 6205.5 ± 469.0 6145.4 ± 721.6 5300.5 ± 481.6
**††† 4437.3 
Mean ± SD; Tot: Total; Cort: Cortical; Peri_C: Periosteal Circumference; Endo_C: 
Endosteal Circumference; SSI: Stress Strain Index; Muscle CSA: Muscle Cross-
sectional Area; ** p < 0.01 significant difference between NOR and SOP groups; ††† p < 
0.001 significant difference between OP and SOP groups 
 
Bone Turnover Markers 
 Table 16 shows the concentrations of bone resorption markers CTX and 
TRAP5b in the four groups. No significant differences in BTMs were found in normal, 




Table 16. Serum Bone Turnover Marker Concentrations 
Variable 
Group 
NOR (n=13) OP (n=46) SOP (n=15) SP (n=1) 
CTX (ng/ml) 0.24 ± 0.17 0.36 ± 0.20 0.33 ± 0.21 0.37 
TRAP5b (U/L) 2.75 ± 1.29 3.53 ± 1.49 3.44 ± 2.01 2.84 
C/T Ratio 0.098 ± 0.078 0.113 ± 0.068 0.101 ± 0.049 0.132 
Mean ± SD; C/T Ratio: CTX/TRAP5b Ratio 
 
Expression of Circulating MiRNAs (c-miRNAs) 
 
 As mentioned in Chapter 3, miRNAs with Ct ≥ 37 were considered not 
expressed since these expression levels indicated large variability (91). As a result, 3 
samples were not expressed in 3 endogenous controls (miR-16, -93, -191), another 3 
sample were not expressed in 2 endogenous controls (miR-93, -191), and 6 samples 
were not expressed in 1 endogenous control (3 of miR-93; 3 of miR-191). In total, 12 
samples were excluded from miRNA analysis due to the lack of quality normalization 
factors from endogenous controls, thus 63 samples were included in miRNA analysis. 
Unfortunately, even for the 63 samples, only about a third of circulating miR-1 (n=23), 
-133a (n=14), -100 (n=24) and none of circulating miR-206 were expressed. Therefore, 
the relative expression levels of the rest of the target miRNAs (miR-21, -23a, -24,  
-125b) between the 4 groups, which are all bone-specific miRNAs, are reported in 
Table 17 and Figure 1 (A-D). In the boxplots shown in Figure 1, the central lines 
indicate the median, boxes reflect first and third quartiles, and error bars indicate 
minimum and maximum values. Biologically, fold change of greater than 2 
(corresponding to a log2-fold change of 1) is considered upregulation, whereas fold 
change of lower than 0.5 (corresponding to a log2-fold change of -1) is considered as 
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downregulation (55). In our study, fold changes ranged from 0.83 to 1.81, and no 
statistical differences were found in the relative expression levels of these miRNAs 
(miR-21, -23a, -24, -125b) among normal, osteopenia, and sarco-osteopenia groups.  
Table 17. Relative Expression Levels of miRNAs based on Muscle and Bone Status  
Mean ± SE; Fold Change 1: Comparison of OP group to NOR group; Fold Change 2: 
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0.51 ± 0.06 
n=12 
0.67 ± 0.10 
n=39 




1.31 1.81 NS 
miR-23a 
n=61 
0.57 ± 0.36 
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Figure 1. Relative Expression Levels of miRNAs Based on Muscle and Bone Status 






 Participants were further compared based on muscle status and bone status 
separately. When comparing the sarcopenia and normal groups, no significant 
differences were observed in the relative expression levels of c-miRNAs (miR-21, -23a, 
-24, -125b) between the two groups and fold changes ranged from 0.86 to 1.66 (Table 
18). Similarly, no significant differences were found in the relative expression levels of 
c-miRNAs (miR-21, -23a, -24, -125b) between normal and osteoporosis groups (Table 
19). However, fold changes of miR-21 (FC=2.59) and miR-23a (FC=2.09) indicated 
upregulation in osteoporosis compared to normal, whereas fold change of miR-125b 
(FC=0.46) indicated downregulation in osteoporosis compared to normal.  
Table 18. Relative Expression Levels of miRNAs in Sarcopenia 
Mean ± SE; NS: No significant difference 
Table 19. Relative Expression Levels of miRNAs in Osteoporosis 
Mean ± SE; NS: No significant difference 
miRNA 
Relative Expression Fold 
Change 
p 
Normal (n=51) Sarcopenia (n=12) 
miR-21 (n=62) 0.63 ± 0.08 (n=51) 0.85 ± 0.40 (n=11) 1.35 NS 
miR-23a (n=62) 0.58 ± 0.18 (n=49) 0.97 ± 0.45 (n=12) 1.66 NS 
miR-24 (n=62) 1.64 ± 0.34 (n=51) 2.14 ± 0.69 (n=11) 1.30 NS 
miR-125b (n=62) 0.64 ± 0.13 (n=44) 0.55 ± 0.19 (n=11) 0.86 NS 
miRNA 
Relative Expression Fold 
Change 
p 
Normal (n=55) Osteoporosis (n=8) 
miR-21(n=62) 0.56 ± 0.06 (n=54) 1.44 ± 0.57 (n=8) 2.59 NS 
miR-23a (n=61) 0.59 ± 0.17 (n=54) 1.22 ± 0.71 (n=7) 2.09 NS 
miR-24 (n=62) 2.21 ± 0.58 (n=54) 1.72 ± 0.45 (n=8) 0.99 NS 
miR-125b (n=55) 0.67 ± 0.12 (n=48) 0.31 ± 0.10 (n=7) 0.46 NS 
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 Table 20 compares the relative expression levels of miRNAs between HRT 
current users and non-users. Since there was a reasonable number of expressed miR-1 
and miR-100 samples in HRT users, comparisons were made in miR-1 and -100 as well. 
No statistical differences in relative expression levels were found between the HRT 
users and non-users groups. Fold changes ranged from 0.23 to 1.57, indicating 
downregulation of miR-1 (FC=0.23) in the HRT users compared to the non-users. 
Table 20. Relative Expression Levels of miRNAs based on HRT Status 
Mean ± SE; NS: No significant difference 
 
c-miRNA and Age 
 Table 21 shows the relationships between the relative expression levels of c-
miRNAs and age. Specifically, the relative expression level of circulating miR-125b 




Relative Expression Fold 
Change 
p 
Non-users (n=48) HRT Users (n=16) 
miR-1 (n=23) 57.15 ± 44.00 (n=16) 13.07 ± 6.18 (n=7) 0.23 NS 
miR-21(n=62) 0.73 ± 0.12 (n=47) 0.51 ± 0.08 (n=15) 0.70 NS 
miR-23a (n=61) 0.66 ± 0.19 (n=46) 0.64 ± 0.35 (n=15) 0.96 NS 
miR-24 (n=62) 1.68 ± 0.36 (n=47) 1.89 ± 0.55 (n=15) 1.13 NS 
miR-100 (n=24) 0.05 ± 0.03 (n=19) 0.05 ± 0.03 (n=5) 1.19 NS 
miR-125b (n=56) 0.55 ± 0.13 (n=42) 0.86 ± 0.22 (n=14) 1.57 NS 
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Table 21. Spearman Correlations between c-miRNAs and Age 
miRNA r p 
miR-1 (n=23) 0.186 0.396 
miR-21 (n=62) 0.048 0.713 
miR-23a (n=61) 0.083 0.525 
miR-24 (n=62) 0.099  0.446 
miR-100 (n=24) 0.040 0.854 
miR-125b (n=56) 0.334 0.012* 
miR-133a (n=14) -0.011 0.970 
* p < 0.05, significant Spearman Correlation Coefficient 
 
 























r = 0.334, p = 0.012 
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c-miRNA and Bone Variables  
 Spearman correlations showed that the relative expression levels of miR-21 
were significantly negatively correlated to the left trochanter BMC (r = -0.252, p = 
0.048) (Figure 3), right trochanter BMC (r = -0.294, p = 0.020) (Figure 4), and cortical 
vBMD at tibia 38% site (r = -0.253, p = 0.047) (Figure 5). There also was a trend for a 
significant association between the relative expression of miR-21 and lumbar spine 
aBMD (r = -0.249, p = 0.051). Furthermore, the relative expression level of miR-23a 
was found to be significantly positively correlated to the level of TRAP5b (r = 0.259, p 
= 0.044) (Figure 6). Although only 23 samples were expressed in circulating miR-1, the 
relative expression level of miR-1 was significantly negatively correlated to cortical 
vBMD at 38% tibia (r = -0.434, p = 0.039). Also, there were trends for significant 
correlations between the relative expression of miR-1 and cortical vBMD at 66% tibia 
(r = -0.379, p = 0.074), and cortical area at 38% tibia (r = 0.395, p = 0.062). The relative 
expression level of miR-133a was positively associated with total body BMC (r = 
0.594, p = 0.025), although only 14 samples were expressed in circulating miR-133a. 
However, no significant correlations were found between other miRNAs (miR-24, -100, 
-125b) and bone variables.  
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r = 0.259, p = 0.044
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c-miRNA and Muscle Variables 
The relative expression level of miR-125b was significantly positively 
correlated with jump velocity (r = 0.263, p = 0.05) and relative jump power (r = 0.294, 
p = 0.028) (Figures 7 and 8). However, none of the muscle-specific circulating miRNAs 
(miR-1, -133a) were correlated with muscle mass, muscle strength, or muscle power.  
 
Figure 7. Correlation between Expression Level of miR-125b and Jump Velocity 
 









































Relative Jump Power (watts/kg)
miR-125b (n=56)
r = 0.294, p = 0.028
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Discussion 
 The current study explored circulating miRNAs (c-miRNAs) that are associated 
with osteoporosis and sarcopenia in postmenopausal women aged 60 to 85 years. Aging 
is accompanied with progressive decline in bone density and muscle mass, known as 
osteoporosis and sarcopenia, respectively. Both osteoporosis and sarcopenia increase 
the risk of falls and fractures and decrease quality of life, which is a great burden to 
society. MiRNAs are short, non-coding RNA molecules that fine tune at least 30% of 
gene expression in humans (129). Recently, circulating miRNAs have been detected 
and shown to be stable in body fluids (e.g. blood), which have significant clinical 
potential as disease-specific biomarkers (70). Although many miRNA studies have 
focused on cancer and cardiovascular diseases, the role of circulating miRNAs in bone 
diseases is becoming more and more recognized (50, 91). The skeletal muscle is 
enriched with muscle-specific miRNAs, such as miR-1, -133a/-133b, -206, which have 
been thoroughly studied in the literature. However, few studies have examined 
circulating miRNAs and muscle characteristics.  
This study compared serum levels of five bone-specific miRNAs (miR-21, -23a, 
-24, -100, -125b) and three muscle-specific miRNAs (miR-1, -133a, -206) in normal, 
osteopenic/osteoporotic, sarcopenic, sarco-osteopenic postmenopausal women. To our 
knowledge, this is the first study examining c-miRNAs in sarcopenia and sarco-
osteopenia. The primary findings were that sarco-osteopenia individuals were at the 
greatest risk of low muscle mass (muscle CSA at 66% of the tibia) and poor functional 
performance (grip strength) compared to normal and osteopenia individuals. Circulating 
miR-21 level was negatively associated with trochanter BMC and cortical vBMD at 
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38% of the tibia, whereas circulating miR-23a level was positively associated with bone 
resorption marker, TRAP5b. In addition, circulating miR-125b level was significantly 
positively associated with age, jump velocity and relative jump power. These 
relationships are in line with the regulatory function of these miRNAs on bone 
homeostasis genes, except for the positive associations between miR-125b and jump 
velocity and relative jump power.  
 This study was designed based on the findings of Seelinger et al. (116), who 
measured miRNAs in serum and bone tissues in osteoporotic patients and 
nonosteoporotic controls using microarrays. They found five miRNAs, miR-21, -23a, -
24, -100, and -125b, that were significantly upregulated in osteoporotic fracture patients 
in both serum and bone tissue compared to controls, and these miRNAs were used in 
our study. In addition, three muscle-specific miRNAs in humans, miR-1, -133, and -
206, regulating muscle development, and proliferation and differentiation of myoblasts 
(117), were used in our study. It is recognized that miR-1 and -133a are highly 
expressed in cardiac and skeletal muscle, whereas miR-206 is primarily expressed in 
slow twitch fibers in skeletal muscle (69).  
Osteoporosis and Sarcopenia Prevalence 
In this study, the prevalence of osteoporosis (aBMD T-score ≤ -2.5) was 13% in 
postmenopausal Caucasian women aged 60 to 85 years. We found that the osteoporotic 
group had significantly lower vBMD, vBMC, and bone strength at most sites of the 
tibia compared to the normal and osteopenia groups. According to a population-based 
study in Minnesota, the prevalence of osteoporosis was approximately 21.6% in women 
in their 60s, 38.5% in their 70s, and as high as 70% in women over age 80 yrs (59). 
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Thus, the prevalence of osteoporosis in our study is lower than their prevalence. The 
discrepancy in findings was probably due to having relative healthy participants in our 
study since we excluded participants with diabetes or uncontrolled hypertension, taking 
antidepressants or glucocorticoids, having recent fractures within 12 months, or having 
metal implants at hip or spine. In addition, our sample size was much smaller than this 
previous study.  
The primary clinical consequence of osteoporosis is fracture, and 
postmenopausal women are at the greatest risk of fractures. It is estimated that the 
lifetime risk of fractures at overall sites was around 40% for U.S. Caucasian women, 
and 13% for U.S. Caucasian men (59). According to the Study of Osteoporotic 
Fractures, osteoporosis at spine or hip contributed to 8-44% of fractures, and the risk of 
fractures was about four-fold in osteoporotic patients compared to those with normal 
aBMD (124). Estrogen plays an important role in regulating bone turnover rate. During 
the menopausal transition, serum estradiol levels decrease by 90%, resulting in the net 
imbalance between bone formation and bone resorption, which causes accelerated bone 
loss, particularly in trabecular bone (40, 103). However, in this study we did not find 
significant associations between current HRT use and osteopenia/osteoporosis status, 
probably due to the wide range of the duration of HRT use (7 months to 45 years).  
 In this study, 21% participants were classified as sarcopenic based on the 
conventional definition. This percentage is slightly lower than the prevalence of 
sarcopenia in the New Mexico Elder Health Survey, which reported that 23.1-43.2% of 
non-Hispanic white females had sarcopenia using the conventional definition (9). The 
new definition of sarcopenia by the EWGSOP combines low muscle mass and poor 
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functional performance, which generates a smaller prevalence of sarcopenia. For 
example, the prevalence of sarcopenia in this study was reduced to 8% based on the 
EWGSOP definition. According to the International Sarcopenia Initiative (24), the 
global prevalence of sarcopenia ranges from 1% to 29% in community dwelling elderly 
using the EWGSOP definition depending on various factors such as gender, age, 
ethnicity, country. One of the challenges in sarcopenia is the lack of consensus about 
the operational definition of sarcopenia and the evaluation of muscle strength and 
function among consensus groups and studies. Some other definitions including the 
International Working Group (IWG) (2009), the Foundation for the National Institutes 
of Health (FNIH) (2014), and Asian Working Group for Sarcopenia (AWGS) (2014), 
all of which use different criteria and cutoff points, making it difficult to compare 
between studies. 
 Currently, no drug therapies are recommended to treat sarcopenia, and the 
management of sarcopenia is based on improving physical activity and diet. Exercise, 
especially resistance exercise, increases muscle mass and strength, improves quality of 
life, and prevents fragility and disability. Therefore, exercise is an effective intervention 
in sarcopenic older adults (109). The review article by Cruz-Jentoft et al. (24) found that 
3-18 months of resistance training alone significantly increased muscle mass, strength 
and functional performance, such as gait speed and chair rise.  
Sarco-Osteopenia 
 In this study, no significant association was found between sarcopenia status and 
osteopenia/osteoporosis status (aBMD T-score ≤ -1.0). However, 20% of the 
participants had both sarcopenia and osteopenia/osteoporosis, known as “sarco-
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osteopenia” (11). Compared to the normal and osteopenia groups, the sarco-osteopenia 
group had significantly lower body weight, jump power, and muscle CSA at 66% of the 
tibia. Additionally, the sarco-osteopenia group had significantly lower grip strength and 
cortical vBMC than the normal group.  
There is an increased risk of fractures with advancing age. Fractures are not only 
due to bone loss, but also associated with other non-skeletal factors, such as gait 
instability and muscle weakness. A major non-skeletal factor that contributes to the risk 
of fracture is falls (127). In fact, over 90% of all fractures occur after a fall (26). Gait 
instability is the major intrinsic risk factor of falls, which is primarily due to muscle 
weakness, or sarcopenia. Therefore, fall prevention is the key to prevent fractures, and 
sarcopenia should be the next focus in fracture prevention (11). Huo et al. (58) assessed 
bone density, functional performance, history of falls and fractures, and nutritional 
status in a large number of older adults (n=680, mean age=79 yr), which had 41% of 
sarco-osteopenia. They found that the sarco-osteopenic group had the highest self-
reported prevalence of falls and fractures than the other groups (normal, 
osteopenia/osteoporosis alone, and sarcopenia alone).  
Exercise, particularly resistance exercise, prevent fractures in two ways. First, 
exercise increases muscle mass and strength and improves balance, which further 
prevents falls. Second, long-term exercise increases BMD and bone strength, which 
prevents fractures. Nutrition is another important aspect in preventing fractures. The 
same study by Huo et al. (58) reported that some nutritional factors, such as levels of 
hemoglobin and serum folate, were associated with sarco-osteopenia status, therefore, 
nutritional considerations are important in fall and fracture prevention in older adults. 
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miRNAs and Osteoporosis 
In this study, we did not find significant statistical differences in levels of c-
miRNAs based on osteoporosis and sarcopenia statuses. However, fold changes of miR-
21 (FC=2.59) and miR-23a (FC=2.09) indicated upregulation in the osteoporosis group, 
whereas fold change of miR-125b (FC=0.46) indicated downregulation in the 
osteoporosis group. Seeliger et al. (116) found that five miRNAs were significantly 
upregulated in osteoporotic hip fracture patients (n=10) in both serum and bone tissue 
compared to non-osteoporotic controls (n=10), including miR-21, -23a, -24, -100, and -
125b. Panach et al. (91) found three c-miRNAs, miR-122, -125b, and -21, that were 
significantly upregulated in osteoporotic hip fracture patients (n=8) compared to 
osteoarthritic controls (n=5). The discrepancy in findings is probably because our 
osteoporotic participants were not fracture patients, and they had no recent fractures 
within the previous 12 months. Levels of specific c-miRNAs between osteoporotic 
participants with and without fractures compared to non-osteoporotic controls might be 
different.  
We found that the relative expression level of miR-21 was significantly 
negatively correlated with the trochanter BMC and cortical vBMD at tibia 38% site. 
Also, there was a trend for significant association between expression of miR-21 and 
lumbar spine aBMD. So far, miR-21 has been one of the most well-studied miRNAs in 
bone diseases. Particularly, circulating miR-21 has been consistently found to be 
upregulated in patients with osteoporotic fractures (91, 116). Panach et al. (91) found 
that the level of miR-21 was correlated with the levels of the bone resorption marker, 
CTX (r =0.76). MiR-21 regulates both osteoblast and osteoclast activities, and it is 
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highly expressed in osteoclast precursors during osteoclastogenesis. One of the 
transcription factors, c-FOS, triggers miR-21 transcription. Meanwhile, miR-21 inhibits 
PDCD4 (programmed cell death protein 4) levels, which inhibits c-FOS. Therefore, a 
positive feedback loop of c-FOS/miR-21/PDCD4 is formed, which promotes RANKL-
induced osteoclastogenesis or bone resorption activity (41). On the other hand, we know 
that estrogen inhibits osteoclastogenesis, and recent research has shown that this 
inhibitory effect is mediated by miR-21 (126). In fact, miR-21 targets on Fas Ligand 
(FASL) gene, which induces osteoclast apoptosis (126). Estrogen deficiency in 
postmenopausal women upregulates miR-21, which decreases the transcription of 
FASL. As a result, it inhibits osteoclast apoptosis and promotes bone resorption 
activity. This may explain the negative relationship between circulating miR-21 and 
bone variables in our findings. The summary is shown in Figure 9.   
 
            Figure 9. Function of miR-21 on Osteoclast 
 
In this study, we found a low positive relationship (r = 0.259) between the 
relative expression level of miR-23a and the level of TRAP5b. TRAP5b, a bone 
resorption marker, is an enzyme released into the circulation during osteoclast activity. 
Research has shown that miR-23a targets RUNX2 pathway in mice, which further 
inhibits the differentiation of osteoblasts (53). Therefore, high levels of miR-23a inhibit 
bone formation, and the net imbalance favors bone resorption. Similarly, high levels of 
TRAP5b indicate a greater number of osteoclasts, which favors bone resorption. The 
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positive relationship between miR-23a and TRAP5b found in this study may be 
attributed to their regulatory roles on bone resorption. The summary is shown in Figure 
10. 
   
               Figure 10. Effects of miR-23a and TRAP5b on Bone 
 
Although many studies have analyzed the role of miRNAs in cancer and 
cardiovascular diseases, the importance of miRNAs in bone metabolism has been 
increasingly recognized only recently. Research has indicated that miRNAs are 
involved in all stages of osteogenesis by regulating differentiation, proliferation, 
apoptosis, and activity of different bone cells: osteocytes, osteoblasts, osteoclasts, and 
chondrocytes. Some miRNAs stimulate osteoblastogenesis, such as miR-15b, -20a, 
whereas some miRNAs inhibit osteoblastogenesis, such as miR-23a, -100, -133a. This 
occurs primarily through regulating BMP-RUNX2 and Wnt signaling pathways. For 
example, miR-100 directly targets BMPR2 (BMP receptor type II) and inhibits 
osteoblastogenesis. Less information is known about the role of miRNAs in osteoclasts 
than osteoblasts. MiR-21 inhibits PCD4 (programmed cell death 4) protein expression 
and induces osteoclastogenesis. The role of miRNAs in osteocytes is unknown, 
however, miRNAs regulate the differentiation and proliferation of chondrocytes. For 
example, miR-125b is reported to stimulate the differentiation of chondrocytes in mouse 
by repressing an inhibitor of chondrogenesis (84).  
Since miRNAs were first detected in plasma in 2008, much more research is 
focusing on circulating miRNAs as biomarkers of diseases (129). MiRNAs are 
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processed through primary miRNAs (pri-miRNA) by the enzyme, Drosha, to form 
precursor miRNAs (pre-miRNA), which are further processed via the enzyme, Dicer, to 
generate mature miRNAs (74). However, the mechanisms of how miRNAs are released 
or taken up by cells are still not clear. In addition, miRNAs have been found to be 
extremely stable in body fluids such as blood, but how miRNAs are protected from 
breakdown in the blood remains unclear. In fact, most studies in miRNAs were 
conducted in various samples, such as tissue, serum, human stem cells, making it 
difficult to compare findings across these studies.  
Although circulating miR-133a was expressed in only 14 samples in this study, 
the relative expression level of miR-133a was positively associated with total body 
BMC, which contradicts previous studies (20, 134). Wang et al. (134) measured 
miRNAs in circulating monocytes (a type of white blood cells) in postmenopausal 
Caucasian women aged 57 to 68 years, and found that circulating miR-133a was highly 
upregulated in low BMD patients (n=10) compared to high BMD patients (n=10). 
Therefore, they concluded that miR-133a might be a monocyte-specific marker for 
osteoporosis. Chen et al. (73) conducted miRNA microarrays in isolated CD14+ (cluster 
of differentiation 14, known as CD14, a human gene) peripheral blood mononuclear 
cells (PBMCs) in Chinese women aged 50 to 59 years. They found that miR-503 was 
significantly downregulated in CD14+PBMCs in osteoporotic patients (n=10) compared 
to the healthy controls (n=10). Furthermore, CD14+PBMC cultures and mice 
experiments confirmed that miR-503 directly targets the RANK gene, which regulates 
osteoclastogenesis. Similarly, they found that miR-133a was significantly upregulated 
in CD14+PBMCs of osteoporotic patients.  
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miRNAs and Sarcopenia 
In our study, we found that the relative expression level of miR-125b was 
significantly positively associated with jump velocity and relative jump power. To date, 
only a few studies have investigated the relationship between c-miRNAs and muscle 
performance, and most of them focused on acute exercise responses (8, 43). Banzet et 
al. (8) reported that the levels of circulating miR-1, -133a, -133b and -208b were 
significantly increased 6 hours after 30-min downhill walking compared to baseline, 
whereas no significant changes were observed after 30-min uphill walking in healthy 
young men (n=9). This result suggested that exercise responses of miRNAs were related 
to exercise mode, with no changes in concentric exercises but significant decreases in 
eccentric exercise. Gomes et al. (43) measured c-miRNA levels (miR-1, -133a, and -
206) in recreational runners (n=5) before and after half marathon, and reported that 
circulating miR-1 (FC=1.3), -133a (FC=1.2), and -206 (FC=4.3) were significantly 
upregulated after a half marathon run. MiR-206 is primarily expressed in slow-twitch 
fibers, and the upregulation of miR-206 reflected the predominance of slow-twitch 
fibers during half marathon. 
Muscle-specific miRNAs, such as miR-1, -206, -208, -133a/-133b, regulate 
many signaling pathways that are involved in muscle metabolism. For example, miR-
23a, not only inhibits osteoblastogenesis in regulating bone metabolism, but also 
inhibits the expression of muscle atrophy genes: Muscle RING Finger I (MuRF1) and 
Muscle Atrophy F-box (MAFbx) (132). MuRF1 and MAFbx are upregulated in muscle 
atrophy (15), therefore the inhibition of MuRF1 and MAFbx by miR-23a results in the 
inhibition of muscle atrophy. On the other hand, miR-21 and -206 inhibit the expression 
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of eIF4E3 (eukaryotic translation initiation factor 4E family member 3) and PDCD10 
(programmed cell death protein 10), which were both decreased during denervation-
induced muscle atrophy. Therefore, the overexpression of miR-21 and -206 causes 
exacerbated muscle atrophy after denervation (123).  
Most of the studies examining muscle-specific miRNAs have been conducted at 
tissue level, and there are different characteristics between tissue-specific miRNAs and 
circulating miRNAs (50), making it difficult to compare findings across studies. Rivas 
et al. (107) compared the miRNA responses to an acute bout of resistance exercise 
between younger and older men. Muscle biopsies were obtained 6 hours after 3 sets of 
10 repetitions of knee extension and leg press exercise at 80% 1RM. MiRNAs from the 
skeletal muscle were analyzed using microarrays. They found that resistance exercise 
induced changes in miRNA expression were only observed in the younger group, 
suggesting impaired miRNA regulation in the older adults. They also reported that the 
overall miRNA score was significantly negatively associated with lower leg lean mass 
at rest combining younger and older participants for their analyses.  
Limitations 
There are several limitations to this study. First, only a small number of samples 
of circulating miR-1 (n=23), -133a (n=14), miR-100 (n=24) and none of circulating 
miR-206 were expressed. MiR-1, -133a, and -206 are all muscle-specific miRNAs; 
thus, we were unable to examine the relationships between muscle-specific miRNAs 
and sarcopenia. Second, there were only 10 participants in the osteoporotic group 
compared to 6-7 times as many participants in the control group, which limited our 
statistical power. Third, only 8 targeted miRNAs that are associated with muscle and 
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bone based on previous literature were included in this study due to the feasibility of the 
cost. Other potential miRNAs that may also be associated with osteoporosis and 
sarcopenia were not studied.  
There are challenges in studying miRNAs as biomarkers. First, no reference 
values of miRNA levels have been established in healthy populations. Second, a better 
method needs to be developed to assess RNA purity. We used the spectrophotometer to 
assess the RNA purity. However, real-time PCR may be a better method to check RNA 
purity since serum RNA concentration is extremely low. In fact, the concentrations of 9 
samples in our study were below the limit of quantification of the spectrophotometer 
although most of them were expressed in miRNA assays. Third, most miRNA 
expression data are relative expression values, and there is no standard normalization 
method since the results are highly dependent on the endogenous controls chosen, the 
technology platform and its technical variation. Thus, it is difficult to compare results 
across studies between different labs and even between studies in the same lab. Fourth, 
the inter-individual variations in levels of circulating miRNAs are not clear. For 
example, physical activity, diet and presumably circadian rhythm have been reported to 
affect the levels of specific c-miRNAs but the exact influences need to be further 
studied (50). Fifth, there are over 2500 miRNAs that have been identified in humans so 
far, and each miRNA may target on multiple genes. Therefore, it is may be better to use 
of a combination of several miRNAs rather than a single miRNA as disease biomarkers. 
Last, the current miRNA tests are not cost-effective, which limits the study of miRNAs 
as clinical biomarkers.  
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Chapter 5 Conclusions 
The primary purpose of the current study was to identify specific circulating 
miRNAs (c-miRNAs) that are associated with bone and muscle status in 
postmenopausal women, and to evaluate the use of these c-miRNAs as biomarkers of 
osteoporosis and sarcopenia. Additional purposes of this study were to determine the 
associations between specific c-miRNAs and bone turnover markers as well as 
sarcopenia parameters.  
Research Questions 
1. Are there significant differences (upregulation/downregulation) in bone-specific c-
miRNAs (miR-21, -23a, -24, -100, and -125b) in postmenopausal women with and 
without osteoporosis?  
No, there were no significant differences in circulating miR-21, -23a, -24, -100, and 
-125b in postmenopausal women with and without osteoporosis. However, miR-21 
(FC=2.59), miR-23a (FC=2.09) suggested upregulation in the osteoporosis group, 
whereas miR-125b (FC=0.46) suggested downregulation in the osteoporosis group. 
2. What are the relationships between these bone-specific miRNAs and bone mass, 
bone strength? 
The relative expression level of miR-21 was significantly negatively correlated to 
left trochanter BMC (r = -0.252, p = 0.048), right trochanter BMC (r = -0.294, p = 
0.02), and cortical vBMD at 38% of the tibia (r = -0.253, p = 0.047). There was a 
trend for significant association between miR-21 level and lumbar spine aBMD (r = 
-0.249, p = 0.051). However, no significant differences were found between the 
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expression levels of other bone-specific miRNAs (miR-23a, -24, -100, and -125b) 
and bone variables.  
3. Are there significant differences (upregulation/downregulation) in skeletal muscle-
specific c-miRNAs (miR-1, -133a, and -206) in postmenopausal women with and 
without sarcopenia?  
Because circulating miR-1, -133a, and -206 were not expressed well in this group of 
postmenopausal women, we were not able to answer this question.  
4. What are the relationships between these muscle-specific c-miRNAs and muscle 
mass, muscle strength, and muscle power? 
According to the available samples that expressed muscle-specific miRNAs, the 
relative expression levels of circulating miR-1 and -133a were not related to muscle 
mass, muscle strength and muscle power.  
Sub Questions 
1. Are bone turnover markers, CTX, TRAP5b and PINP, associated with bone-specific 
miRNAs? 
Yes. The relative expression levels of miR-23a were significantly and positively 
correlated to the levels of bone resorption marker, TRAP5b (r = 0.259, p = 0.044).  
No relationships were found between miRNAs and CTX. In addition, P1NP results 
were inconsistent thus were not used in data analysis. 
Clinical Significance 
Though this study did not determine that these specific circulating miRNAs 
were biomarkers of osteoporosis and sarcopenia, we found that circulating miR-21 was 
significantly negatively correlated some bone variables, and circulating miR-125b was 
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significantly negatively correlated with age, which gives us possible ideas to further 
explore characteristics of circulating miRNAs in a variety of populations. In addition, 
we found that the sarco-osteopenic individuals were at the greatest risk of poor 
functional performance. Therefore, sarco-osteopenia individuals should be the next 
focus in fall and fracture prevention.  
Suggestions for Future Research 
MiRNA precursors (pri-miRNA, pre-miRNA) and target genes need to be 
studied to better understand the functions of target miRNAs. Other target miRNAs are 
needed to get a comprehensive understanding, and miRNA microarray is a better tool to 
analyze a large number of circulating miRNAs in one sample. For example, studies 
indicated that the miR-29 family (miR-29a, -29b, -29c) is a key mediator of osteoclast 
differentiation, and miR-31 is highly upregulated during RANKL-induced 
osteoclastogenesis (41). Clinical populations, such as osteoporotic facture patients, as 
well as exercise responses in healthy populations, are promising directions to study 
miRNA profiles. Exercise interventions may be a better approach to study muscle-
specific circulating miRNAs (miR-1, -133a, -206) in aging, since most of them were not 
expressed at rest in postmenopausal women in our study but changed in response to 
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Appendix I: Non-expressed and Expressed Samples in miR-100 and -133a 
Table 22. Comparison between Non-expressed and Expressed Samples of miR-100 
Variable Non-Express (n=39) Express (n=24) P 
Age (yr) 67.9 ± 5.7 72.2 ± 5.6 0.005 
Height (cm) 164.4 ± 5.5 160.2 ± 7.6 0.026 
Total aBMC (g) 2410.9 ± 368.4 2169.5 ± 296.0 0.009 
JHt (inch) 7.8 ± 2.2 6.6 ± 1.9 0.030 
Ca2+ (mg/day) 1367.2 ± 614.8 1780.6 ± 830.7 0.027 
BPAQ Past 104.2 ± 93.0 56.3 ± 41.8 0.021 
BPAQ Total 54.1 ± 46.7 29.6 ± 21.7 0.019 
Tot vBMC (mg/mm) 38% 
 
304.5 ± 33.4 282.7 ± 25.7 0.008 
Cort vBMC (mg/mm) 289.1 ± 34.2 266.6 ± 27.8 0.009 
Cort Area (mm2) 248.3 ± 30.7 230.2 ± 22.5 0.015 
SSI (mm3) 1405.4 ± 210.5 1298.7 ± 194.2 0.049 
Total vBMC (mg/mm) 66% 329.4 ± 40.6 299.1 ± 33.5 0.003 
Cort vBMC (mg/mm) 289.8 ± 40.0 260.2 ± 41.7 0.008 
Cort Area (mm2) 260.4 ± 36.0 235.4 ± 31.8 0.007 
Ipolar (mm4) 36167 ± 7215 32008 ± 6003 0.021 
SSI (mm3) 2076.5 ± 317.4 1858.5 ± 260.4 0.006 
Mean ± SD; JHt: Jump Height; Ca2+: Calcium Intake; Tot: Total; Cort: Cortical; SSI: 
Stress Strain Index 
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Table 23. Comparison between Non-expressed and Expressed Samples of miR-
133a 
Variable Non-Express (n=49) Express (n=14) P 
Age (yr) 68.8 ± 6.2 72.3 ± 4.5 0.005 
Total aBMD (g/cm2) 1.139 ± 0.103 1.078 ± 0.081 0.009 
JHt (inch) 7.7 ± 2.1 6.0 ± 2.1 0.030 
BPAQ Past 97.7 ± 85.2 44.8 ± 43.1 0.021 
BPAQ Total 50.7 ± 42.8 23.9 ± 22.9 0.019 
Tot vBMD  (mg/cm3) 4% 
 
275.3 ± 34.4 242.7 ± 42.6 0.004 
Tot Area (mm2) 965.7 ± 101.1 1056.1 ± 138.5 0.004 
Trab vBMD (mg/cm3) 237.5 ± 31.6 207.4 ± 40.3 0.036 
Trab Area (mm2) 796.7 ± 90.7 877.5 ± 123.0 0.036 
Peri_C (mm) 110.0 ± 5.8 115.0 ± 7.7 0.039 
Tot BSI (mg2/mm4)  73.9 ± 17.3 62.5 ± 18.7 0.037 
Trab BSI (mg2/mm4) 45.6 ± 12.0 38.1 ± 13.0 0.047 
Tot vBMD (g/cm3) 38% 882.1 ± 73.2 818.4 ± 77.0 0.006 
Cort vBMC (mg/mm) 285.0 ± 33.1 264.7 ± 31.4 0.046 
Endo_C (mm) 34.5 ± 4.6 38.0 ± 5.0 0.018 
Tot vBMD (g/cm3) 66% 642.7 ± 81.4 580.2 ± 103.4 0.020 
Cort vBMC (mg/mm) 284.3 ± 41.1 258.5 ± 44.2 0.045 
Mean ± SD; JHt: Jump Height; Tot: Total; Trab: Trabecular; Peri_C: Periosteal 
Circumference; Cort: Cortical; Endo_C: Endosteal Circumference 
 
